[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2020163637A1 - Bisphosphonate-linked compounds - Google Patents

Bisphosphonate-linked compounds Download PDF

Info

Publication number
WO2020163637A1
WO2020163637A1 PCT/US2020/017071 US2020017071W WO2020163637A1 WO 2020163637 A1 WO2020163637 A1 WO 2020163637A1 US 2020017071 W US2020017071 W US 2020017071W WO 2020163637 A1 WO2020163637 A1 WO 2020163637A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
kbu2046
pharmaceutically acceptable
cells
crystal
Prior art date
Application number
PCT/US2020/017071
Other languages
French (fr)
Inventor
Raymond Bergan
Ryan Gordon
Anhinandan PATTANAYAK
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Priority to JP2021545859A priority Critical patent/JP2022523146A/en
Priority to EP20752874.6A priority patent/EP3920906A4/en
Priority to US17/428,951 priority patent/US20220133894A1/en
Priority to CA3128239A priority patent/CA3128239A1/en
Publication of WO2020163637A1 publication Critical patent/WO2020163637A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Definitions

  • the present invention concerns novel compounds useful in the treatment of cancer[Steve, a novel use of the compound is to treat a side-effect of the cancer - bone destruction - should this also be mentioned here?], particularly including compounds linking a bisphosphonate moiety with KBU2046, and pharmaceutically acceptable salts, co-crystals, polymorphs, solvates, hydrates, and enantiomers thereof.
  • KBU2046 3-(4-fluorophenyl)chroman-4-one
  • KBU2046 a first-in-class HSP90 activity modulator
  • US Patent Application Publication No. 2016/0128973 Bosset et al. - Northwestern University
  • KBU2046 inhibits metastasis across murine models of human prostate and breast cancer, decreases bone destruction, and prolongs survival at nanomolar concentrations after oral administration.
  • metastatic cancers that locate to the bone, including metastatic cancers of the breast, prostate, lung, kidney, thyroid, bladder, esophagus, stomach, liver, pancreas, testicles, skin, head and neck, lymphomas, multiple myelomas, and sarcomas from the soft tissue or bone.
  • Z is selected from the group of: rii in each instance is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
  • X is (-CH 2 -) n2 ;
  • Ri is selected from the group of H and Ci-C 3 alkyl
  • R 2 is selected from the group of H and OH; n 2 is an integer selected from the group of 0, 1, 2, and 3; n 3 is an integer selected from the group of 0 and 1; and Y is a bisphosphonate compound; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • Ri is selected from the group of methyl and ethyl.
  • Ri is methyl
  • Ri is ethyl
  • Ri is H.
  • R 2 is H.
  • R 2 is OH
  • ni is an integer selected from the group of 1, 2, 3, 4, and 5.
  • ni is an integer selected from the group of 1, 2, 3, and 4.
  • Y is selected from structures of the group below, indicated by their corresponding bisphosphonate entity:
  • the waving or oscillating line passing through a solid line ( X) indicates the bond through which adjacent atoms are bound.
  • FIGURE 1A graphs the effect of chemotherapy on the growth of androgen independent PC3-M PCa cells in vitro.
  • FIGURE IB graphs the effect of chemotherapy on the growth of androgen independent PCa cells in vivo.
  • FIGURE 2A graphs lung metastasis measured by qPCR for human Alu sequences, expressed as percent control
  • FIGURE 2B represents weekly IVIS imaging of tumor.
  • FIGURE 2C indicates corresponding tumor weight in tested mice.
  • FIGURE 3A indicates effects on AR-responsive gene selection in LNCaP cells treated with R1881 (R), KBU2046 (46) and/or enzalutamide.
  • FIGURE 3B indicates effects on AR-responsive gene selection in VCaP cells treated with R1881 (R), KBU2046 (46) and/or enzalutamide.
  • FIGURE 3C depicts effects of enzalutamide on LNCaP cell growth.
  • FIGURE 3D depicts effects of enzalutamide on VCaP cell growth.
  • FIGURE 3E represents effects on AR activation through Western blots of nuclear (N) and cytoplasmic (C) preparations of cell extracts probed for AR, laminin B1 or a-tubulin.
  • FIGURE 3F graphs the effect on tumor outgrowth after androgen deprivation therapy in LNCaP/AR-luc cells implanted subcutaneously into castrate mice, followed by KBU2046 treatment.
  • FIGURE 3G graphs the effect on tumor outgrowth after androgen deprivation therapy in LNCaP/AR-luc cells implanted orthotopically into castrate mice, followed by KBU2046 treatment.
  • FIGURE 4A provides Western blot representations of protein production following KBU2016 administration in RAW 267.4 cells.
  • FIGURE 4B depicts effects on cell morphology when RAW 267.4 cells were treated with RANKL and with KBU2046.
  • FIGURE 4C demonstrates tartrate resistant acid phosphatase expression in treated cells.
  • FIGURE 4D graphs bone degradation as quantified bone surface area.
  • FIGURE 5A graphs bone degradation as quantified bone surface area when RAW 267.4 cells were treated with KBU2046, zoledronic acid, or the combination.
  • FIGURE 5B depicts effects on bone degradation when RAW 267.4 cells were treated with KBU2046, zoledronic acid, or the combination.
  • FIGURE 5C-E graphs cell viability, cytotoxicity and apoptosis, as measured by a Triplex Assay, when RAW 267.4 cells were treated with KBU2046, zoledronic acid, or the combination.
  • FIGURE 5F depicts effects on bone degradation, measured by computed tomography, after intra-cardiac injection of human PC3 prostate cancer cells when mice were treated with KBU2046, zoledronic acid, or the combination.
  • FIGURES 6G and 6H represent the effect of compound G herein in inhibiting osteoclast- mediated bone degradation.
  • FIGURES 61 and 6J represent the effect of compound FI herein in inhibiting osteoclast-mediated bone degradation.
  • FIGURES 6K and 6L represent the effect of compound I herein in inhibiting osteoclast-mediated bone degradation.
  • FIGURE 7 represents the effects of experimental compound in the inhibition of PCa cell motility.
  • FIGURE 13 represents KBU2046 does not inhibit activity of adriamycin in MDA-MB-231 cells.
  • FIGURE 14 represents KBU2046 does not inhibit activity of adriamycin in PC3-M cells.
  • FIGURE 15 represents KBU2046 does not inhibit activity of vinblastine in MDA-MB-231 cells.
  • FIGURE 16 represents KBU2046 does not inhibit activity of vinblastine in PC3-M cells.
  • FIGURE 17 represents KBU2046 does not inhibit activity of taxol in MDA-MB-231 cells.
  • FIGURE 18 represents KBU2046 does not inhibit activity of taxol in PC3-M cells.
  • Ri, R2, , X, Y, and Z are as defined for Formula (I), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof. Also provided is a compound of Formula (lb):
  • Ri, R 2 , ni, X, Y, and Z are as defined for Formula (I), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • Ri, R 2 , X, Y, and Z are as defined for Formula (I), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • Another embodiment provides a compound of Formula (lc), wherein Ri is selected from the group of FI and methyl; and is an integer selected from the group of 1, 2, and 3; n3 is an integer selected from the group of 1 and 2; and Z is selected from the group of: or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • Ri is selected from the group of FI and methyl; and is an integer selected from the group of 1, 2, and 3; n3 is an integer selected from the group of 1 and 2; and Z is selected from the group of: or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • n 3 is 0 and Ri is methyl.
  • n3 is 1.
  • ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
  • X is (-CH 2 -)n 2 ; n 2 is an integer selected from 0, 1, 2, and 3; and Y is a bisphosphonate compound; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • a further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein ni is an integer selected from the group of 1, 2, 3, 4, and 5; and n2, X, and Y are as defined for Formula (Id), above.
  • a still further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, and 4; and n2, X, and Y are as defined for Formula (Id), above.
  • Z is selected from the group of: ; ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6; and n3 is an integer selected from the group of 0 and 1; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • a further embodiment provides a compound of Formula (II), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, 4, and 5; and n 2 is an integer selected from the group of 0 and 1.
  • a still further embodiment provides a compound of Formula (II), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein ni is an integer selected from the group of 1, 2, 3, and 4; and n 2 is an integer selected from the group of 0 and 1. Also provided is a compound of Formula (lla), or a pharmaceutically acceptable salt thereof:
  • ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6.
  • a further embodiment provides a compound of Formula (lla), , or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, 4, and 5.
  • a further embodiment provides a compound of Formula (lla), , or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, and 4.
  • ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
  • X is (-CH -)n ; and n 2 is an integer selected from 0, 1, 2, and 3.
  • a further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein ni is an integer selected from the group of 1, 2, 3, 4, and 5; and n2 and X are as defined Formulas (lll)-(XI), above.
  • a further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, and 4; and n2 and X are as defined Formulas (lll)-(XI), above.
  • Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI) there is a separate embodiment in which the integer represented by is 1, 2, or 3.
  • references herein to Formulas (l)-(XI) include all formulas, including Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI).
  • composition comprising a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, and a pharmaceutically acceptable carrier or excipient.
  • Additional methods include those specifically to cancers of the bone that originate as, and are metastatic from, cancers of the breast, prostate, lung, kidney, thyroid, bladder, esophagus, stomach, liver, pancreas, testicles, skin, head and neck, lymphomas, multiple myelomas, and sarcomas from the soft tissue or bone.
  • a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof such as, but not limited to, a hormone therapeutic agent or a chemotherapeutic agent.
  • the hormone therapeutic agent can be an antiestrogen (e.g., tamoxifen, toremifene, fulvestrant, raloxifene, droloxifene, idoxifene and the like), progestogens (e.g., megestrol acetate and the like) aromatase inhibitors (e.g., anastrozole, letrozole, exemestane, vorozole, exemestane, fadrozole, aminoglutethimide, exemestane, l-methyl-l,4-androstadiene-3,17-dione and the like), anti androgens (e.g., bicalutimide, nilutamide, flutamide, cyproterone acetate, and the like), luteinizing hormone releasing hormone agonist (LHRH Agonist) (e.g., goserelin, leuprolide,
  • LHRH Agonist
  • chemotherapy agents such as cisplatin, carboplatin, oxaliplatin, Eloxatin, (iii) anti-metabolites, such as Methotrexate, 5-fluorouracil (e.g., capecitabine), gemcitabine (2'-deoxy-2',2'-difluorocytidine monohydrochloride (.beta.
  • anti-metabolites such as Methotrexate, 5-fluorouracil (e.g., capecitabine), gemcitabine (2'-deoxy-2',2'-difluorocytidine monohydrochloride (.beta.
  • anthracyclines such as daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, adriamycin, bleomycin, mitomycin-C, dactinomycin, mithramycin
  • taxanes such as paclitaxel, docetaxel, Taxotere, Taxol, taxasm, 7-epipaclitaxel, t-acetyl paclitaxel, 10-desacetyl-paclitaxel, 10-desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7- epipaclitaxel, 7-
  • a method of treatment of osteoporosis in a subject comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
  • the subject in need of treatment of osteoporosis is a postmenopausal woman.
  • the subject in need of treatment of osteoporosis is a man with osteoporosis.
  • ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6. Further provided are compounds of the formula:
  • Pi is an integer selected from the group of 1, 2, 3, 4, 5, and 6.
  • Compounds as described herein may be prepared by methods known in the art. Specific examples of synthetic routes are presented. The method below for the preparation of 3-(4- fluorophenyl)-7-hydroxychroman-4-one (Compound A) may also be seen in U.S. 2016/0128973 Al.
  • Compound A may be converted to 2-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)acetic acid, Compound B, by methods described in Chemical & Pharmaceutical Bulletin, 39(10), 2681-90; 1991, as follows.
  • compound A may also be converted to the corresponding carbonate compound, 3-(4- fluorophenyl)-4-oxochroman-7-yl phenyl carbonate, Compound C, as follows at from 0°-RT (room temperature) for about an hour.
  • Zolendronic acid can be converted to 3-(3-amino-2-hydroxypropyl)-l-(2-hydroxy-2,2- diphosphonoethyl)-lH-imidazol-3-ium, Compound D, as follows.
  • Nosyl group protection was performed with PEG-1 followed by N-alkylation on 0.5 g scale and isolated 0.4 g of compound 3.
  • Nosyl deprotection of compound 3 was accomplished on 0.4 g [PhSH (1 eq.) / K 2 C0 3 (2.5 eq.) / DMF / RT] scale.
  • Work up followed by purification provided 0.14 g of desired compound 4.
  • 0.7 g of compound 4 was isolated after two steps of PEG-1 on 2 g scale.
  • Coupling of compound 4 with compound F was done on 0.25 g [F (1.1 eq.) / triphosgene (0.5 eq.) / DIPEA (2 eq.) / DCM / 0 °C / lh] scale.
  • Step-1 CBZ protection (Step-1) was performed on 5 g scale with 3-(methylamino)propanol (SM 1) followed by O-alkylation (Step-2), we have isolated 4.5 g of compound 5.
  • CBZ deprotection (Step-2) of compound 5 was carried out on 4.5 g [Pd-C / H2 /MeOH / RT] scale to achieve 2.6 g of compound 6.
  • a coupling reaction between amine intermediate 6 with triphosgene has been attempted on 500 mg [triphosgene (0.5 eq.) /NaHCOs/CI-hCh /DMF/H2O/ 0°C to RT] scale.
  • SM remains unreacted even after 12 h.
  • KBU2046 does not interfere with the activity of chemotherapy
  • Chemotherapy is widely used in the treatment of androgen independent PCa, both docetaxel and cabazitaxel have been shown to prolong life (Tannock et al., N EnglJ Med 351, 1502-1512 (2004); Sweeney et al., N EnglJ Med 373, 737-746 (2015); and Bono et al., Lancet 376, 1147-1154 (2010)), and both are taxanes that target microtubule function, thereby inhibiting cell growth ( Lyseng-Williamson et al., Drugs 65, 2513-2531, 2005). Combining chemotherapy with KBU2046 did not affect the ability of either docetaxel or cabazitaxel to inhibit the growth of androgen independent PC3-M cells in vitro (Fig. 1A).
  • Figure 1 demonstrates KBU2046 does not inhibit chemotherapy efficacy against prostate cancer.
  • Figure IB depicts the effect of chemotherapy on the growth of androgen independent PCa cells in vivo.
  • Unregulated cell growth and unregulated cell movement constitute two elemental processes of cancer.
  • a therapeutic strategy wherein both of these processes are targeted is rationally-based.
  • the PC3-M orthotopic implantation murine model allows for the quantification of primary tumor growth, the assessment of distant metastasis to the lungs, and has previously been used to measure the effects of therapy and genetic alterations on metastasis (Xu et al., Nature
  • mice received orthotopic implants of PC3-M-luc cells, were treated with 0, 10 or 20 mg/kg docetaxel, and tumor growth monitored with weekly IVIS imaging. Docetaxel significantly inhibited growth compared to controls in a dose-dependent manner. Subsequently, mice with orthotopic implants of PC3-M-luc cells were treated with docetaxel, KBU2046, docetaxel+KBU2046 or vehicle, as denoted, and effects on primary tumor growth and lung metastasis quantified (Figs. 2A, 2B, and 2C). Prior studies demonstrated that it is possible to detect as few as 10 human cells per mouse organ, i.e.
  • docetaxel+KBU2046 is 42% reduction, giving an experimental/calculated ratio of 1.1, or additive-to- slightly-synergistic.
  • Figure 2 demonstrates that KBU2046 plus docetaxel exhibits increased anti-metastatic efficacy.
  • Cohorts of N 10 mice bearing orthotopic implants of PC3-M-luc cells were treated daily with 150 mg/kg KUB2046 (46), intraperitoneal docetaxel 7.5 mg/kg weekly (doc), the combination (doc+46), or with oral and intraperitoneal vehicle (CO).
  • KBU2046 treatment began 3 days before implantation and docetaxel began 1 week after.
  • A Lung metastasis measured by qPCR for human Alu sequences, expressed as percent control
  • B Weekly I VIS imaging of tumor.
  • C Tumor weight. *denotes P ⁇ 0.05 for differences between cohorts denoted by bars. All data are mean ⁇ SEM.
  • KBU2046 does not interfere with hormone therapy
  • Hormonal therapy is the mainstay of treatment for metastatic PCa ( N. C. C. Network, Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) Version 4, (2016)). It is therefore important to ensure other therapeutic modalities do not interfere with it.
  • Initial hormone treatment involves decreasing testicular androgen production, and is termed androgen deprivation therapy (ADT).
  • ADT androgen deprivation therapy
  • Disease progression which is inevitable, is termed castrate-resistant PCa, and is commonly treated with an androgen receptor (AR) antagonist, such as enzalutamide (Beer et al., N Engl J Med 371, 424-433 (2014)).
  • AR androgen receptor
  • KBU2046 significantly inhibited R1881-mediated PSA gene expression, consistent with inhibition of AR function.
  • AR is a client protein of HSP90
  • AR function requires HSP90- mediated chaperone action, and direct inhibitors of HSP90 decrease client protein expression and inhibit AR function (24-26 Fang et al., J Biol Chem 271, 28697-28702 (1996); Saporita et al., Prostate 67, 509- 520 (2007); and Ni et al., Mol Cell Biol 30, 1243-1253 (2010)).
  • KBU2046 is not a direct inhibitor of HSP90, and as such does not globally decrease client protein expression.
  • FISP90 activity modulator SFIAM
  • KBU2046 It is a selective FISP90 activity modulator (SFIAM), and selectively modulates client proteins that regulate cell motility.
  • SFIAM selective FISP90 activity modulator
  • the effect of KBU2046 on AR expression and function had not been examined.
  • functional AR translocates from the cytoplasm to the nucleus, and nuclear localization therefore provides a measure of functional AR.
  • R1881, KBU2046, and/or enzalutamide By treating LNCaP and VCaP cells with R1881, KBU2046, and/or enzalutamide, and measuring AR expression by Western blot in resultant nuclear and cytoplasmic cellular fractions, we demonstrated that KBU2046 did not affect AR expression or nuclear localization in response to R1881, nor its inhibition by enzalutamide (Fig. 3E).
  • KBU2046 did not alter tumor growth in either model. Taken together, these findings support the notion that KBU2046 does not affect androgen signaling, nor does it inhibit the efficacy of ADT or of AR antagonist therapy.
  • Figure 3 helps demonstrate that KBU2046 also does not affect androgen signaling nor therapeutic targeting.
  • LNCaP or VCaP cells cultured in hormone free media were treated with R1881 (R), KBU2046 (46) and/or enzalutamide (E).
  • R R1881
  • KBU2046 (46) enzalutamide
  • E enzalutamide
  • E Effects on AR activation. Western blots of nuclear (N) and cytoplasmic (C) preparations of cell extracts were probed for AR, laminin
  • PCa cells secrete interleukin (IL)-ll and parathyroid hormone-related protein (PTHrP), stimulating osteoblasts to secrete receptor activator of nuclear factor kappa-B ligand (RANKL), RANKL induces osteoclasts to degrade bone, degradation of bone matrix releases insulin growth factor (IGF) and transforming growth factor (TGF) , which act to sustain PCa cell growth.
  • IGF insulin growth factor
  • TGF transforming growth factor
  • RAW 267.4 cells differentiate into mature osteoclasts.
  • RAW 267.4 cells differentiate into mature osteoclasts.
  • Upon maturation osteoclast become multinucleated, express tartrate resistant acid phosphatase (TRAP), and have the capacity to form actin rings that create an occluded cavity in which bone is degraded.
  • TRIP tartrate resistant acid phosphatase
  • KBU2046 inhibits phosphorylation of Rail's activation motif in RANKL treated RAW 267.4 osteoclast cells, and does so in a time-dependent manner (Fig. 4A).
  • RAW 267.4 cells with KBU2046 induces several structural and functional changes. It reduces RANKL-mediated formation of multinucleated cells, and those that do form have lower numbers of nuclei (see 40x panels, Fig. 4B).
  • the characteristic prominent actin ring (white arrow) surrounding the resorptive cavity (yellow arrow) is readily apparent in control cells treated with RANKL ligand, but is lacking in KBU2046-treated cells (100*, panels). Consistent with it inhibiting maturation of RAW 267.4 cells, TRAP staining is decreased in KBU2046-treated cells (Fig. 4C).
  • RAW 267.4 cells exhibit a phenotype characterized by isolated cells with long thin cytoplasmic extensions (Fig. 4B).
  • treatment with KBU2046 markedly reduces cellular extensions, demonstrating that its ability to induce effects on RAW 267.4 cells is not RANKL dependent.
  • Figure 4 represents the KBU2046 inhibition of osteoclast function.
  • Figure 4A compares effects on Rafl activation.
  • RAW 267.4 cells were treated with RANKL for 4 days, treated with 10 mM KBU2046 for the indicated time periods, and Western blot for the denoted proteins performed.
  • B Effects on cell morphology.
  • RAW 267.4 cells were treated with RANKL and with KBU2046 for 4 days, or not, and denoted, and stained for actin (green) and DAPI (blue); white arrow denotes an actin ring, yellow arrow a resorptive cavity. Representative immunofluorescent images are depicted.
  • C Tartrate resistant acid phosphatase (TRAP) expression.
  • Bisphosphonates modify the bone microenvironment by chemically binding to calcium-phosphate bone mineral, are then taken up by osteoclasts after they digest the bound mineral and once inside the cell, they inhibit osteoclast-mediated bone degradation (Polascik et al., Ther Clin Risk Manag 4, 261-268 (2008)).
  • ZA bisphosphonate, zoledronic acid
  • ZA is used clinically to decrease bone fractures in men with metastatic PCa (Saad et al., J Natl Cancer Inst 94, 1458-1468 (2002); Saad et al., J Natl Cancer Inst 96, 879-882 (2004); and James et al., JAMA Oncol 2, 493-499 (2016) ).
  • ZA is administered to humans by injection, whereupon it binds to bone mineral, while the remainder is rapidly cleared from the body, and that bound to bone mineral is responsible for inhibition of osteoclast activity and resultant decrease in bone fractures in men with metastatic PCa (N. Pharmaceuticals, Zoledronic Acid package insert FDA approved drug package insert, (2007)).
  • Figure 5 represents the improved efficacy seen with KBU2046 combined with ZA.
  • bone degradation was tested using osteo assays performed as in Figure 4D.
  • Cells were treated with KBU2046 (46), ZA at 2, 10 or 20 mM, with the indicated combinations, or vehicle (control; CO).
  • Figure 5B provides representative photomicrographs of osteo assay wells. Black color denotes presence of bone matrix; RL: RANKL.
  • C-E Cell viability, cytotoxicity and apoptosis.
  • Treatment was oral 150 mg KBU2046/kg daily (starting 3 days before 1C injection), intraperitoneal ZA 100 pg/kg weekly (starting 1 week before 1C injection), with oral and intraperitoneal vehicle controls given as indicated.
  • F Representative computed tomography images. Image types are: side view and coronal sections of skull, and axil and sagittal sections of the femurs. Red arrows denote areas of bone destruction.
  • C and D Quantification of bone lesions. The macroscopic lesions in the jaw were quantified by direct measurement from CT images, and expressed as the mean ⁇ SEM percent of control. Bone density of femurs was measured from CT images, and expressed as the mean ⁇ SEM percent of control. *denotes P ⁇ 0.05 compared to control, and for groups indicated by bars.
  • Findings in control cells are consistent with this process, demonstrating successive decreases in cell viability, accompanied by increases in cellular cytotoxicity and apoptosis with time.
  • Findings with KBU2046 are consistent with it delaying the maturation process, and include significant increases in cell viability and decreases in cytotoxicity at 72 hours, compared to control (P ⁇ 0.05).
  • the combination of ZA+KBU2046 significantly increased apoptosis and cytotoxicity at 48 hours, but there was little-to-no effect on viability at 72 hours.
  • mice develop widespread metastasis to the bone, with those to the mandible being the most prominent and symptomatic.
  • Mice were treated with either ZA, KBU2046, ZA+KBU2046 or vehicle (control), and at the end of the experiment CT images of the bones were obtained and metastasis to the mandible and femur quantified (Figs. 5F-H).
  • ZA did not impair KBU2046 efficacy.
  • bone density was significantly (P ⁇ 0.05) improved as compared to control by 56 ⁇ 2.7% and 22 ⁇ 2.4% with ZA or KBU2046 treatment, respectively.
  • the combination of ZA+KBU2046 resulted in significant (P ⁇ 0.05) additive efficacy compared to either standalone treatment, significantly increasing density by 76 ⁇ 3.7% as compared to the control treatment cohort.
  • metastasis is responsible for over 90% of mortality (40), and for PCa it is responsible for essentially 100% (41, 42 Norgaard et al J Urol 184, 162-167 (2010); and Pound et al JAMA 281, 1591-1597 (1999)).
  • KBU2046 and its ability to serve as a SHAM agent, selectively inhibiting Rafl activation, precision targeting of cell motility and resultant metastasis is now possible.
  • Increased cancer cell motility is a characteristic of cancer which represents a clinically relevant driver of morbidity and mortality, and constitutes an important therapeutic target that we can now access. As such, we believe it is centrally important to consider it as one of several abnormal functions.
  • anti-motility therapy can be deployed in a combined non-interfering manner with multiple classes of agents previously established to have efficacy in humans. Specifically, we demonstrate sustained efficacy in conjunction with several differentially acting cytotoxic chemotherapeutic agents, and do so in cell culture based studies as well as in two murine models, one utilizing subcutaneous and one utilizing orthotopic implantation. In the case of ZA, an agent that modifies the bone microenvironment, we also demonstrate that anti-motility therapy does not interfere with its activity. If fact we demonstrate that it enhances it. Here too, experiments spanned cell culture based and human murine xenograft based models of bone destruction.
  • Docetaxel + KBU2046 not only retained the growth inhibitory efficacy of docetaxel but also exhibited additive efficacy at inhibiting metastasis.
  • Docetaxel is a cytotoxic chemotherapeutic agent that inhibits cell growth and induces cell death through apoptosis, and is widely used across several cancer types inclusive of PCa. Such a strategic approach would be applicable to existing clinical scenarios where docetaxel is used to treat PCa, especially in the newly diagnosed metastatic setting, where the combination would serve to decrease formation of secondary metastasis. Because robust pre-clinical systemic models of the formation of metastasis as a function of targeting the androgen axis are lacking, we have not demonstrated that KBU2046 would provide additive
  • KBU2046 will inhibit the motility of androgen- responsive PCa cell lines (Xu et al, above). Further, KBU2046 did not interfere with AR antagonist therapy mediated by enzalutamide, a widely used agent shown to decrease metastasis in humans (Hussain et al., N EnglJ Med 378, 2465-2474 (2016)).
  • a multi-functional therapy approach may provide a platform to scale back ZA dosing, minimizing the potential for osteonecrosis while retaining protection against bone related events.
  • the effects upon tumor growth and formation of metastasis were measured in athymic mice given orthotopic implants of PC3-M cells, and measuring primary tumor growth and quantifying metastasis to the lungs.
  • the effects of hormone therapy on cell growth and PSA expression were measured on LNCaP or VCaP cells grown in vitro, while effects on tumor growth evaluated LNCaP-AR cells implanted either subcutaneously or orthotopically.
  • the ability of KBU2046 and ZA to inhibit bone destruction was measured by adding osteoclasts to Osteo-Assay plates, and measuring pit formation. Inhibition of bone destruction in athymic mice was measured by CT scan of animals after intracardiac injection of PC3 cells. Inhibition of Rafl phosphorylation in osteoclasts was measured by Western blot, while changes in the actin cytoskeleton and cell morphology were measured by immunofluorescent microscopy.
  • the following prostate cancer cells lines, PC-3, LNCaP, and VCaP were obtained from American Type Culture Collection, the constitutively active luciferase expressing PC3-Luc cell line was obtained from PerkinElmer, the origin a characteristics of PC3-M cells have been previously described by us (Liu et al., Prostate cancer and prostatic diseases 4, 81-91 (2001)).
  • the constitutively active luciferase expressing PC3-M-luc cell line was established by transducing the parental cell line with pGL4.50 luciferase reporter (Promega), and culturing under hygromycin selection for stable integration.
  • the LNCaP/AR-luc cell line was kindly provided by Charles Sawyers (Tran et al, Science 324, 787-790 (2009)).
  • the osteoclasts precursor mouse macrophage cell line Raw 264.7 was obtained from American Type Culture Collection. All cells were cultured as previously described ( Xu et al. above; Liu et al., Prostate cancer and prostatic diseases 4, 81-91 (2001); and Korenchuk et al., In Vivo 15, 163- 168 (2001), were maintained at 37°C in a humidified atmosphere of 5% carbon dioxide with biweekly media changes. All cell lines were drawn from stored stock cells, and replenished on a standardized periodic basis and were routinely monitored for Mycoplasma (PlasmoTestTM, InvivoGen, San Diego, CA).
  • Cells were authenticated by the following: they were acquired from the originator of that line, grown under quarantine conditions, expanded and stored as primary stocks and not used until following conditions were met: mycoplasma negative; through morphologic examination; growth characteristics; hormone responsiveness or lack thereof.
  • KBU2046 was synthesized as previously described (5).
  • Enzalutamide (#S1250), docetaxel (#S1148) and zoledronic acid (#S1314) were purchased from
  • Enzalutamide mediated growth inhibition was assessed using Sulforhodamine B (SRB) growth inhibition assays, were performed as previously described (49).
  • SRB Sulforhodamine B
  • LNCaP and VCaP cells were pre-incubated in the charcoal-striped medium containing 10 pM KBU2046 or vehicle control for 72 hours. Cells were then stimulated with 1.0 nM R1881 and treated for 24-hours with 10 pM KBU2046 or vehicle control in the presence or absence of 10 pM enzalutamide.
  • the nuclear and cytosolic subcellular fractions of the cells were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce, Waltham, MA) according to the manufacturer's instructions. Protein was quantified by BCA assay (Thermo-Fisher Scientific, Waltham, MA), per manufacturer's instructions.
  • Pierce ECL western blotting substrate (#32106) and SuperSignal West Femto maximum sensitivity substrate (#34096) were purchased from Thermo Scientific. All primary antibodies were used at a dilution of 1:1000 and corresponding secondary antibodies used at a dilution of 1:5000.
  • DylightTM Phallodin (#12935) was purchased from Cell Signaling Technology.
  • Raw 264.7 cells were grown in differentiation medium (described below), with or without KBU2046, for 4 days on a Chamber Slide (Nunc Lab-Tek). Chambers were washed once with PBS, followed by 10-minute fixation in cold 10% neutral-buffered formalin (VWR) and a post-fixation wash with PBS. Permeabilization was achieved with incubation in 0.1% Triton X-100 (Sigma) for 5 minutes, and then blocked overnight at 4°C with 1% BSA (Sigma) containing 10% goat serum (Thermo Fisher
  • RAW 264.7 cells were suspended in osteoclasts differentiation media (MEM- alpha (Gibco) with 10% FBS, 1% antibiotic-antimycotic and 50 ng/ml RANKL (EMD Millipore, R0525- 10UG)) and plated in 96 well Osteo Surface Assay plates (Corning) at 5000 cells per well.
  • MEM- alpha Gibco
  • FBS fetal bovine serum
  • RANKL EMD Millipore, R0525- 10UG
  • Osteo Surface Assay plates Corning
  • the osteosurface was pre-coated for 30 minutes at 25°C with a 0, 2, 10, or 20 mM solution of ZA suspended in sterile water, followed by a gentle rinsing in PBS to remove free compound prior to plating of cells.
  • the ApoTox-Glo triplex assay (Promega) was performed to assess cell viability, cytotoxicity and caspase-3/7 activation, per manufacturer's instructions.
  • 5000 Raw 264.7 cells were plated in 96- well assay plates and cultured in the osteoclasts differentiation media for four days at which point the media was replenished with or without KBU2046 and cell responses measured after 24, 48, and 72 hrs following the manufactures protocol.
  • PCa subcutaneous implantation 2.5 x 10 5 PC3-M cells in sterile PBS were implanted into the right flank of 6-7 week old male athymic nude mice (Charles River) and tumor growth measurements were performed twice a week as previously described by us ( Gordon et al., Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One 9, el04271 (2014)).
  • Experimental groups were randomly assigned to cages prior to the initiation of the study. Tumor measurements were obtained in a blinded fashion, and tumor volumes were calculated with the following formula: length x (width) 2 x 0.5.
  • PCa orthotopic implantation Orthotopic implantation of 2.5 x 10 5 PC3M-luc into 7-8 week old male athymic mice was performed as previously described by us (5, 52 Xu et al., above; and Pavese et al., J Vis Exp, e50873 (2013)).
  • Daily oral gavage treatment with 150mg/kg KBU2046 or was initiated 3 days prior to implantation and continued throughout the duration of the study.
  • Weekly IP injections with 7.5 mg/kg docetaxel or control were administered beginning one week post implantation.
  • Primary tumor out growth was monitored via weekly IVIS imaging. At the completion of the study the primary tumor was resected and weighed and lungs were resected and snap frozen.
  • the snap frozen tissue was pulverized, DNA isolated and Alu- sequencing performed as previously described (19).
  • the following custom TaqMan primer probe set was utilized: forward primer (101 F) GGTGAAACCCCGTCTCTACT, reverse primer (206 R) GGTTCAAGCGATTCT CCTGC, and hydrolysis probe (144RH) CGCCCGGCTAATTTTTGTAT.
  • the 144RH probe was labeled with a 5' fluorescent reporter (6-FAM) and a 3' fluorescent quencher (Black Hole Quencher).
  • the relative content of human DNA was calculated with using the comparative C T method, C T (sample) - C T (negative control). All samples were run in triplicate and were repeated.
  • Castration resistant PCa subcutaneous implantation 6-7 week old male athymic mice received trans-scrotal bilateral orchiectomy with a single incision in the midline of scrotums under general anesthesia and then allowed to recover for 10 days. Following the recovery period mice received a subcutaneous implantation of 2.0 x 10 s LNCaP/AR-luc into the right flank as previously described by us (Gordon et al., PLoS One 9, el04271 (2014)). Treatment with 80mg/kg KBU2046 or control was administered via oral gavage 5 times weekly starting 4 weeks post-implantation, prior to the emergence of the castration resistant phenotype, and continued for 12 weeks. Experimental groups were randomized prior to the initiation of treatment. Twice weekly tumor measurements were performed and androgen receptor activity monitored biweekly through IVIS imaging.
  • Castration resistant PCa orthotopic implantation Castrations of athymic mice were performed as described above, and following a two-week recovery period orthotopic implantations of 5.0 x 10 5 LNCaP/AR-luc were performed as previously described by us (Xu et al., above; and, Pavese et al., above). Biweekly IVIS imaging was performed to assess androgen receptor activity and treatment with 80mg/kg KBU2046 or control via oral gavage 5 times weekly began 12 weeks post-implantation, as the castration resistant phenotype began to emerge, and continued for duration of 4 weeks. Experimental groups were randomly assigned to cages prior to the initiation of the study.
  • PCa intracardiac (1C) injection 1C injection of 4.0 x 10 5 PC3-luc cells into the left ventricle of 7-8 week old athymic mice under ultrasound guidance was performed as previously described by us (Xu et al., above). Weekly IP injections of 100 pg/kg ZA or vehicle control (PBS) began 7 days prior to the 1C injection and continued throughout the duration of the study, whereas daily oral gavage treatment with 150mg/kg KBU2046 or control began 3 days prior to the 1C injection. All treatments were randomly assigned to cages prior to the initiation of the study. IVIS imaging was performed 30 min post 1C injection to confirm systemic distribution of cells and conducted weekly starting 7 days post injection, continuing for a period of 4 weeks.
  • Computed Tomograpgy (CT) radiographic imaging of the entire cohort was performed with an Inveon X-ray pCT scanner (Inveon, Siemens) at the completion of the study.
  • Bone disruption of the mandible was assessed in a blinded fashion utilizing the MPR of the mandible.
  • the loss of bone in the periodontal cavity was calculated by measuring the distance between the edge of molar root and the wall of periodontal cavity at both coronal and transverse planes.
  • Figures 6A through 6L Experimental compounds inhibit osteoclast mediated bone degradation.
  • RAW 267.4 cells were plated onto Osteo Assay plates, in differentiation medium containing RANKL and the experimental compounds (or vehicle control) at the concentration indicated on day 0, medium was replenished with RANKL and treatments on day 3 day of the assay.
  • Figures 8A and 8B Experimental compounds inhibit movement of human prostate cancer cells.
  • I VIS imaging was performed weekly, and at the end of the experiment, computed tomography (CT) scans performed and the degree of bone destruction in the jaw quantified.
  • * denotes P ⁇ / 0.05 by 2-sided Student's t test for comparisons between cohorts indicated by bars.
  • KBU2046 does not inhibit the efficacy of chemotherapy
  • the compounds of the disclosure may possess an asymmetric center, and can be produced as a racemic mixture or as individual enantiomers.
  • the individual enantiomers may be obtained by asymmetric synthesis or by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis.
  • the individual enantiomers may also be obtained by resolution of the compound by conventional means, such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column.
  • HPLC high pressure liquid chromatography
  • the term “comprising” may include the embodiments “consisting of” and “consisting essentially of.”
  • the terms “comprise(s),” “include(s),” “having,” “has,”“can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps.
  • compositions or processes as “consisting of and “consisting essentially of the enumerated ingredients/steps, which allows the presence of only the named ingredients/steps, along with any impurities that might result therefrom, and excludes other ingredients/steps.
  • therapeutically effective amount refers to an amount that is sufficient to effect treatment, as defined below, when administered to a subject (e.g., a mammal, such as a human) in need of such treatment.
  • the therapeutically or pharmaceutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • a "therapeutically effective amount” or a “pharmaceutically effective amount” of a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof is an amount sufficient to modulate a physiological expression or activity, and thereby treat a subject (e.g., a human) suffering an indication, or to ameliorate or alleviate the existing symptoms of the indication.
  • a therapeutically or pharmaceutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of activity.
  • the pharmaceutically effective dose per administration may be from about 1 mg to about 200 mg.
  • the pharmaceutically effective dose may be from about 5 mg to about 150 mg per dose.
  • the pharmaceutically effective dose may be from about 5 mg to about 100 mg per dose.
  • the pharmaceutically effective dose may be from about 1 mg to about 50 mg.
  • a medical professional may provide the dosage in a once- weekly regimen or divide the dosage into equal daily doses.
  • a single or divided dose may be administered every 1, 2, 3, 4, 5, or 6 months.
  • Treatment is an approach for obtaining beneficial or desired results including clinical results.
  • beneficial or desired clinical results may include one or more of the following: (i) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); (ii) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition);
  • inhibiting the disease or condition e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition
  • slowing or arresting the development of one or more clinical symptoms associated with the disease or condition e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e
  • inhibiting indicates a decrease, such as a significant decrease, in the baseline activity of a biological activity or process.
  • “Inhibition of a given activity” refers to a decrease in the activity as a direct or indirect response to the presence of a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, relative to the activity of the condition in the absence of such compound or a pharmaceutically acceptable salt or co-crystal thereof.
  • the decrease in activity may be due to the direct interaction of the compound with a biological target, or due to the interaction of the compound(s) described herein with one or more other factors that in turn affect the specific activity.
  • the presence of the compound(s) may decrease an activity by directly binding to the target, by causing (directly or indirectly) another factor to decrease the activity, or by (directly or indirectly) decreasing the amount of a factor present in the cell or organism.
  • the inhibition of the specified activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.
  • the term "inhibitor" is understood to refer to a compound or agent that, upon administration to a human in need thereof at a pharmaceutically or therapeutically effective dose, provides the inhibition activity desired.
  • Delaying the development of a disease or condition means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease or condition, and/or subject being treated.
  • a method that "delays" development of a disease or condition is a method that reduces probability of disease or condition development in a given time frame and/or reduces the extent of the disease or condition in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a statistically significant number of subjects.
  • Disease or condition development can be detectable using standard methods, such as routine physical exams, mammography, imaging, or biopsy. Development may also refer to disease or condition progression that may be initially undetectable and includes occurrence, recurrence, and onset.
  • significant is meant any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p ⁇ 0.05.
  • “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid.
  • Examples of salts may include hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate (mesylate), benzenesuflonate (besylate), p-toluenesulfonate (tosylate), 2- hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate (such as acetate, HOOC-(CH 2 ) n -- COOH where n is 0-4).
  • the free base can be obtained by basifying a solution of the acid salt.
  • an addition salt particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds.
  • Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts.
  • crystal forms and related terms herein refer to the various crystalline modifications of a given substance, including, but not limited to, polymorphs, solvates, hydrates, co-crystals, and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, other molecular complexes of salts, and polymorphs thereof. Crystal forms of a substance can be obtained by a number of methods, as known in the art.
  • Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces such as, e.g., in nanopores or capillaries, recrystallization on surfaces or templates, such as, e.g., on polymers, recrystallization in the presence of additives, such as, e.g., co-crystal counter-molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, grinding and solvent-drop grinding.
  • additives such as, e.g., co-crystal counter-molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, grinding and solvent-drop grinding.
  • co-crystal or "co-crystal salt” as used herein means a crystalline material composed of two or more unique solids at room temperature, each of which has distinctive physical characteristics such as structure, melting point, and heats of fusion, hygroscopicity, solubility, and stability.
  • a co-crystal or a co-crystal salt can be produced according to a per se known co-crystallization method.
  • co-crystal (or cocrystal) or co-crystal salt also refer to a multicomponent system in which there exists a host API (active pharmaceutical ingredient) molecule or molecules, such as a compound of Formula I, and a guest (or co-former) molecule or molecules.
  • the pharmaceutically acceptable co-crystal of the compound of Formula I or of the compound of Formula II with a co-former molecule is in a crystalline form selected from a malonic acid co-crystal, a succinic acid co-crystal, a decanoic acid co-crystal, a salicylic acid co-crystal, a vanillic acid co-crystal, a maltol co-crystal, or a glycolic acid co-crystal.
  • Co-crystals may have improved properties as compared to the parent form (i.e., the free molecule, zwitter ion, etc.) or a salt of the parent compound.
  • Improved properties can include increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, a crystalline form of a normally amorphous compound, a crystalline form of a difficult to salt or unsalable compound, decreased form diversity, more desired morphology, and the like.
  • subject and/or “patient” refers to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment.
  • the methods described herein may be useful in both human therapy and veterinary applications.
  • the subject is a mammal; in some embodiments the subject is human; and in some embodiments the subject is chosen from cats and dogs.
  • Subject in need thereof or “human in need thereof” refers to a subject, such as a human, who may have or is suspected to have diseases or conditions that would benefit from certain treatment; for example treatment with a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, as described herein. This includes a subject who may be determined to be at risk of or susceptible to such diseases or conditions, such that treatment would prevent the disease or condition from developing.
  • pharmaceutically acceptable excipient is a pharmaceutically acceptable vehicle that includes, without limitation, any and all carriers, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • pharmaceutically acceptable vehicle includes, without limitation, any and all carriers, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • carrier refers to an excipient or vehicle that includes without limitation diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, and the like with which the compound is administered. Carriers are generally described herein and also in “Remington's Pharmaceutical Sciences” by E. W. Martin.
  • Examples of carriers include, but are not limited to, aluminum monostearate, aluminum stearate, carboxymethylcellulose, carboxymethylcellulose sodium, crospovidone, glyceryl isostearate, glyceryl monostearate, hydroxyethyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxyoctacosanyl hydroxystearate, hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 188, poloxamer 237, poloxamer 407, povidone, silicon dioxide, colloidal silicon dioxide, silicone, silicone adhesive 4102, and silicone emulsion. It should be understood, however, that the carriers selected for the pharmaceutical compositions, and the amounts of such carriers in the composition, may vary depending on the method of
  • diluent generally refers to a substance that is used to dilute the compound of interest prior to delivery. Diluents can also serve to stabilize compounds. Examples of diluents may include starch, saccharides, disaccharides, sucrose, lactose, polysaccharides, cellulose, cellulose ethers, hydroxypropyl cellulose, sugar alcohols, xylitol, sorbitol, maltitol, microcrystalline cellulose, calcium or sodium carbonate, lactose, lactose monohydrate, dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, mannitol, microcrystalline cellulose, and tribasic calcium phosphate.
  • disintegrant generally refers to a substance which, upon addition to a solid preparation, facilitates its break-up or disintegration after administration and permits the release of an active ingredient as efficiently as possible to allow for its rapid dissolution.
  • disintegrants may include maize starch, sodium starch glycolate, croscarmellose sodium, crospovidone,
  • microcrystalline cellulose modified corn starch, sodium carboxymethyl starch, povidone, pregelatinized starch, and alginic acid.
  • precipitation inhibitors generally refers to a substance that prevents or inhibits precipitation of the active agent from a supersaturated solution.
  • a precipitation inhibitor includes hydroxypropylmethylcellulose (HPMC).
  • surfactants generally refers to a substance that lowers the surface tension between a liquid and a solid that could improve the wetting of the active agent or improve the solubility of the active agent. Examples of surfactants include poloxamer and sodium lauryl sulfate.
  • glidant generally refers to substances used in tablet and capsule formulations to improve flow-properties during tablet compression and to produce an anti-caking effect.
  • examples of glidants may include colloidal silicon dioxide, talc, fumed silica, starch, starch derivatives, and bentonite.
  • binder generally refers to any pharmaceutically acceptable film which can be used to bind together the active and inert components of the carrier together to maintain cohesive and discrete portions.
  • binders may include hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, copovidone, and ethyl cellulose.
  • lubricant generally refers to a substance that is added to a powder blend to prevent the compacted powder mass from sticking to the equipment during the tableting or encapsulation process.
  • a lubricant can aid the ejection of the tablet form the dies, and can improve powder flow.
  • examples of lubricants may include magnesium stearate, stearic acid, silica, fats, calcium stearate, polyethylene glycol, sodium stearyl fumarate, or talc; and solubilizers such as fatty acids including lauric acid, oleic acid, and Cs/Cio fatty acid.
  • compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal or
  • compositions may be administered alone or in combination with other therapeutic agents.
  • pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).
  • compositions may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
  • agents having similar utilities for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
  • One mode for administration is parenteral, particularly by injection.
  • the forms in which the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, may be
  • incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
  • Aqueous solutions in saline may also conventionally be used for injection.
  • Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Sterile injectable solutions are prepared by incorporating a compound according to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • sterile injectable solutions are prepared containing a therapeutically effective amount, e.g., 0.1 to 1000 mg, of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof.
  • the effective amount will be from about 0.1 mg to about 100 mg per dose.
  • the dosage will be from about 5 mg to about 75 mg per dose. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.
  • Oral administration is another route for administration of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof. Administration may be via capsule or enteric coated tablets, or the like.
  • the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients in an oral formulation include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions as described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770;
  • transdermal delivery devices patches
  • Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present disclosure in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139.
  • patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • each dosage unit contains from 0.1 mg to 1 g, 0.1 mg to 700 mg, or 0.1 mg to 100 mg of a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof.
  • the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof.
  • a pharmaceutical excipient for preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof.
  • these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills as described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation may include solutions and suspensions in
  • compositions comprising the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
  • the compounds, pharmaceutical compositions, and methods of treatment herein may be used in combination with other forms of cancer treatment, including chemotherapy, other bone directed therapy, inclusive of bisphosphonates or denosumab, hormone therapy, radiation therapy, surgery, small molecule therapeutics (imatinib, cisplatin, doxorubicin, Ifosfamide, methotrexate, vincristine, cyclophosphamide, etoposide, dactinomycin, eribulin mesylate, larotrectinib, pazopanib, trabectedin), including inhibitors of protein kinases, interferon, mTOR inhibitors (rapamycin, temsirolimus, everolimus, ridaforolimus), PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, AZD2281), biologies, including antibodies (trastuzumab, den
  • the compounds herein may be administered in combination treatments utilizing chemotherapeutic agents such as taxol, vinblastine, vincristine, Ifosfamide (IFEX ® ), doxorubicin (ADRIAMYCIN ® ), etoposide, methotrexate, cisplatin, dactinomycin, denosumab, and cyclophosphamide (CYTOXAN ® ), or combinations thereof.
  • chemotherapeutic agents such as taxol, vinblastine, vincristine, Ifosfamide (IFEX ® ), doxorubicin (ADRIAMYCIN ® ), etoposide, methotrexate, cisplatin, dactinomycin, denosumab, and cyclophosphamide (CYTOXAN ® ), or combinations thereof.
  • the compounds herein may be utilized in combination therapies with additional agents, such as alendronate (FOSOMAX ® ), risedronate
  • compositions comprising the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, can be prepared and placed in an appropriate container, and labeled for treatment of an indicated condition.
  • an article of manufacture such as a container comprising a unit dosage form of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, and a label containing instructions for use of the compounds.
  • the article of manufacture is a container comprising a unit dosage form of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, and at least one pharmaceutically acceptable vehicle.
  • the article of manufacture may be a bottle, vial, ampoule, single-use disposable applicator, or the like, containing the pharmaceutical composition provided in the present disclosure.
  • the container may be formed from a variety of materials, such as glass or plastic and in one aspect also contains a label on, or associated with, the container which indicates directions for use in the treatment of cancer of the bone.
  • the active ingredient may be packaged in any material capable of improving chemical and physical stability, such as an aluminum foil bag.
  • diseases or conditions indicated on the label can include, for example, treatment of cancer of the bone which is original in origin to bone.
  • the label may be directed to treatment of a cancer that has metastasized to the bone.
  • Any pharmaceutical composition provided in the present disclosure may be used in the articles of manufacture, the same as if each and every composition were specifically and individually listed for use in an article of manufacture.
  • kits that includes a compound of Formula I, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof.
  • kit that includes a compound of Formula II, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof.
  • the kit comprises a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof.
  • the kit comprises a compound of Formula II, or a pharmaceutically acceptable salt or co-crystal thereof.
  • the kit may comprise a label and/or instructions for use of the compound in the treatment of a disease or condition in a subject (e.g., human) in need thereof.
  • the disease or condition may be associated with or mediated by the intended activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns novel compounds useful in the treatment of cancer, particularly including compounds linking a bisphosphonate moiety with KBU2046, and pharmaceutically acceptable salts, co-crystals, polymorphs, solvates, hydrates, and enantiomers thereof, as well as methods for their production and pharmaceutical compositions comprising them.

Description

BISPHOSPHONATE-LINKED COMPOUNDS
FIELD OF THE INVENTION
The present invention concerns novel compounds useful in the treatment of cancer[Steve, a novel use of the compound is to treat a side-effect of the cancer - bone destruction - should this also be mentioned here?], particularly including compounds linking a bisphosphonate moiety with KBU2046, and pharmaceutically acceptable salts, co-crystals, polymorphs, solvates, hydrates, and enantiomers thereof.
BACKGROUND OF THE INVENTION
3-(4-fluorophenyl)chroman-4-one (KBU2046), a first-in-class HSP90 activity modulator, may be synthesized as described in US Patent Application Publication No. 2016/0128973 (Bergan et al. - Northwestern University), titled Inhibition of Cancer Cell Motility. KBU2046 inhibits metastasis across murine models of human prostate and breast cancer, decreases bone destruction, and prolongs survival at nanomolar concentrations after oral administration.
There remains a need for improved delivery and efficacy of oncology agents for the treatment of cancers of the bone, including metastatic cancers that locate to the bone, including metastatic cancers of the breast, prostate, lung, kidney, thyroid, bladder, esophagus, stomach, liver, pancreas, testicles, skin, head and neck, lymphomas, multiple myelomas, and sarcomas from the soft tissue or bone.
BRIEF SUMMARY OF THE INVENTION
Provided is a compound of the formula:
Figure imgf000002_0001
Z is selected from the group of:
Figure imgf000003_0001
rii in each instance is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
X is (-CH2-)n2;
Ri is selected from the group of H and Ci-C3 alkyl;
R2 is selected from the group of H and OH; n2 is an integer selected from the group of 0, 1, 2, and 3; n3 is an integer selected from the group of 0 and 1; and Y is a bisphosphonate compound; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
In some embodiments, Ri is selected from the group of methyl and ethyl.
In some embodiments, Ri is methyl.
In some embodiments, Ri is ethyl.
In other embodiments, Ri is H.
In some embodiments, R2 is H.
In other embodiments R2 is OH.
In some embodiments, ni is an integer selected from the group of 1, 2, 3, 4, and 5.
In some embodiments, ni is an integer selected from the group of 1, 2, 3, and 4.
In some embodiments, Y is selected from structures of the group below, indicated by their corresponding bisphosphonate entity:
Figure imgf000004_0001
O O
Etidronate Clodronate Tiludronate
Figure imgf000004_0002
Pamidronate Alendronate Olpadronate
Figure imgf000004_0003
HO
Minodronate Neridronate
Zoledronate
In the structures herein, the waving or oscillating line passing through a solid line ( X, indicates the bond through which adjacent atoms are bound.
BRIEF DESCRIPTION OF THE MANY VIEWS OF THE DRAWINGS
FIGURE 1A graphs the effect of chemotherapy on the growth of androgen independent PC3-M PCa cells in vitro. FIGURE IB graphs the effect of chemotherapy on the growth of androgen independent PCa cells in vivo.
FIGURE 2A graphs lung metastasis measured by qPCR for human Alu sequences, expressed as percent control
FIGURE 2B represents weekly IVIS imaging of tumor.
FIGURE 2C) indicates corresponding tumor weight in tested mice.
FIGURE 3A indicates effects on AR-responsive gene selection in LNCaP cells treated with R1881 (R), KBU2046 (46) and/or enzalutamide.
FIGURE 3B indicates effects on AR-responsive gene selection in VCaP cells treated with R1881 (R), KBU2046 (46) and/or enzalutamide.
FIGURE 3C depicts effects of enzalutamide on LNCaP cell growth.
FIGURE 3D depicts effects of enzalutamide on VCaP cell growth.
FIGURE 3E represents effects on AR activation through Western blots of nuclear (N) and cytoplasmic (C) preparations of cell extracts probed for AR, laminin B1 or a-tubulin.
FIGURE 3F graphs the effect on tumor outgrowth after androgen deprivation therapy in LNCaP/AR-luc cells implanted subcutaneously into castrate mice, followed by KBU2046 treatment.
FIGURE 3G graphs the effect on tumor outgrowth after androgen deprivation therapy in LNCaP/AR-luc cells implanted orthotopically into castrate mice, followed by KBU2046 treatment.
FIGURE 4A provides Western blot representations of protein production following KBU2016 administration in RAW 267.4 cells.
FIGURE 4B depicts effects on cell morphology when RAW 267.4 cells were treated with RANKL and with KBU2046.
FIGURE 4C demonstrates tartrate resistant acid phosphatase expression in treated cells.
FIGURE 4D graphs bone degradation as quantified bone surface area.
FIGURE 5A graphs bone degradation as quantified bone surface area when RAW 267.4 cells were treated with KBU2046, zoledronic acid, or the combination. FIGURE 5B depicts effects on bone degradation when RAW 267.4 cells were treated with KBU2046, zoledronic acid, or the combination.
FIGURE 5C-E graphs cell viability, cytotoxicity and apoptosis, as measured by a Triplex Assay, when RAW 267.4 cells were treated with KBU2046, zoledronic acid, or the combination.
FIGURE 5F depicts effects on bone degradation, measured by computed tomography, after intra-cardiac injection of human PC3 prostate cancer cells when mice were treated with KBU2046, zoledronic acid, or the combination.
FIGURE 5G-FI graphs effects on bone degradation in the mandible and femur, quantified by computed tomography, after intra-cardiac injection of human PC3 prostate cancer cells when mice were treated with KBU2046, zoledronic acid, or the combination.
FIGURES 6A and 6B represent the effect of compound E (n=l) herein in inhibiting osteoclast- mediated bone degradation.
FIGURES 6C and 6D represent the effect of compound E (n=2) herein in inhibiting osteoclast- mediated bone degradation.
FIGURES 6E and 6F represent the effect of compound E (n=3) herein in inhibiting osteoclast- mediated bone degradation.
FIGURES 6G and 6H represent the effect of compound G herein in inhibiting osteoclast- mediated bone degradation.
FIGURES 61 and 6J represent the effect of compound FI herein in inhibiting osteoclast-mediated bone degradation.
FIGURES 6K and 6L represent the effect of compound I herein in inhibiting osteoclast-mediated bone degradation.
FIGURE 7 represents the effects of experimental compound in the inhibition of PCa cell motility.
FIGURES 8A and 8B represent transwell migration and transwell invasion of PC3 cells treated with 10 micromolar Compound E (n=l).
FIGURE 9 represents PC3 cell viability under exponential growth and one day later following 10 micromolar treatment of Compound E (n=l). FIGURE 10 represents raw 267.4 cells under exponential growth and treated with RANKL and micromolar treatment of Compound E (n=l).
FIGURES 11A and 11B represent degrees of mice jaw bone destruction quantified following treatment with compound E (n=l).
FIGURE 12 represents survival of mice following treatment with compound E (n=l) 1 week prior to cardiac injection with PC3-luc cells.
FIGURE 13 represents KBU2046 does not inhibit activity of adriamycin in MDA-MB-231 cells.
FIGURE 14 represents KBU2046 does not inhibit activity of adriamycin in PC3-M cells.
FIGURE 15 represents KBU2046 does not inhibit activity of vinblastine in MDA-MB-231 cells.
FIGURE 16 represents KBU2046 does not inhibit activity of vinblastine in PC3-M cells.
FIGURE 17 represents KBU2046 does not inhibit activity of taxol in MDA-MB-231 cells.
FIGURE 18 represents KBU2046 does not inhibit activity of taxol in PC3-M cells.
DETAILED DESCRIPTION OF THE INVENTION
The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
Also provided is a compound of Formula (la):
Figure imgf000007_0001
wherein, Ri, R2, , X, Y, and Z are as defined for Formula (I), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof. Also provided is a compound of Formula (lb):
Figure imgf000008_0001
wherein, Ri, R2, ni, X, Y, and Z are as defined for Formula (I), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided is a compound of Formula (lc):
Figure imgf000008_0002
wherein, Ri, R2, X, Y, and Z are as defined for Formula (I), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Another embodiment provides a compound of Formula (lc), wherein Ri is selected from the group of FI and methyl; and is an integer selected from the group of 1, 2, and 3; n3 is an integer selected from the group of 1 and 2; and Z is selected from the group of:
Figure imgf000008_0003
or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof. Within each of the embodiments above for a compound of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, there is a further embodiment wherein n3 is 0 and Ri is hydrogen.
Within each of the embodiments above for a compound of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, there is a further embodiment wherein n3 is 0 and Ri is methyl.
Within each of the embodiments above for a compound of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, there is a further embodiment wherein Z is:
Figure imgf000009_0001
Within each of the embodiments above for a compound of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, there is a further embodiment wherein Z is:
Figure imgf000009_0002
Within each of the embodiments above for a compound of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, there is a further embodiment wherein n3 is 0.
Within each of the embodiments above for a compound of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, there is a further embodiment wherein n3 is 1.
Provided is a compound of Formula (Id):
Figure imgf000010_0001
wherein: ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
X is (-CH2-)n2; n2 is an integer selected from 0, 1, 2, and 3; and Y is a bisphosphonate compound; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
A further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein ni is an integer selected from the group of 1, 2, 3, 4, and 5; and n2, X, and Y are as defined for Formula (Id), above.
A still further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, and 4; and n2, X, and Y are as defined for Formula (Id), above.
Also provided is a compound of Formula (II), or a pharmaceutically acceptable salt thereof:
Figure imgf000011_0001
wherein:
Z is selected from the group of:
Figure imgf000011_0002
; ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6; and n3 is an integer selected from the group of 0 and 1; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
A further embodiment provides a compound of Formula (II), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, 4, and 5; and n2 is an integer selected from the group of 0 and 1.
A still further embodiment provides a compound of Formula (II), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein ni is an integer selected from the group of 1, 2, 3, and 4; and n2 is an integer selected from the group of 0 and 1. Also provided is a compound of Formula (lla), or a pharmaceutically acceptable salt thereof:
Figure imgf000012_0001
wherein ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6.
A further embodiment provides a compound of Formula (lla), , or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, 4, and 5.
A further embodiment provides a compound of Formula (lla), , or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, and 4.
Specific examples of compounds of Formula (II) include:
Figure imgf000012_0002
Compound G: (2-(3-(3-(3-(2-(2-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)acetamido)ethoxy) propanamido)-2-(ll-oxidaneyl)propyl)-lH-3l4-imidazol-l-yl)-l-hydroxyethane-l,l-diyl)bis(hydrogen phosphonate)
Figure imgf000013_0001
Compound H: (2-(3-(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-15-(ll-oxidaneyl)-2,12-dioxo-6,9- dioxa-3,13-diazahexadecan-16-yl)-lH-3l4-imidazol-l-yl)-l-hydroxyethane-l,l-diyl)bis(hydrogen phosphonate)
Figure imgf000013_0002
Compound I: (2-(3-(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-18-(ll-oxidaneyl)-2,15-dioxo-6,9,12- trioxa-3,16-diazanonadecan-19-yl)-lH-3l4-imidazol-l-yl)-l-hydroxyethane-l,l-diyl)bis(hydrogen
phosphonate)
Figure imgf000014_0001
(2-(3-(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-21-(ll-oxidaneyl)-2,18-dioxo-6,9,12,15- tetraoxa-3,19-diazadocosan-22-yl)-lH-3l4-imidazol-l-yl)-l-hydroxyethane-l,l-diyl)bis(hydrogen phosphonate).
It is understood in the structures related to compounds of Formula (II), that a positive charge may also be indicated for the 3-position nitrogen in the imidazolyl ring, as follows.
Figure imgf000014_0002
Further provided as separate embodiments are compounds of Formula (III), Formula (IV), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), and Formula (XI), or a pharmaceutically acceptable salt thereof:
Figure imgf000014_0003
Figure imgf000015_0001
Figure imgf000016_0001
wherein, in each of Formulas (lll)-(XI): ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
X is (-CH -)n ; and n2 is an integer selected from 0, 1, 2, and 3.
A further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein ni is an integer selected from the group of 1, 2, 3, 4, and 5; and n2 and X are as defined Formulas (lll)-(XI), above.
A further embodiment provides a compound of Formula (Id), above, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein is an integer selected from the group of 1, 2, 3, and 4; and n2 and X are as defined Formulas (lll)-(XI), above. Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 1, 2, or 3. Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is another separate embodiment in which the integer represented by is 1 or 2. Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 3 or 4.
Within each of the compound embodiments described herein using (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 1.
Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 2.
Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 3.
Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 4.
Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by is 5.
Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by ni is 6.
Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by n3 is 0. Within each of the compound embodiments described herein using Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI), there is a separate embodiment in which the integer represented by n3 is 1.
It is understood that references herein to Formulas (l)-(XI) include all formulas, including Formulas (I), (la), (lb), (lc), (Id), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), and (XI).
Within each of the compound descriptions referenced above for Formulas (l)-(XI), there is a separate embodiment having the same descriptions, otherwise, wherein X is 0. Within each of the compound descriptions referenced above for Formulas (l)-(XI), there is a separate embodiment having the same descriptions, otherwise, wherein X is 1 or 2. Within each of the compound descriptions referenced above for Formulas (l)-(XI), there is a separate embodiment having the same descriptions, otherwise, wherein X is 2 or 3. Within each of the compound descriptions referenced above for Formulas (l)-(XI), there is also a separate embodiment having the same descriptions, otherwise, wherein X is 3 or 4.
Further provided herein is a pharmaceutical composition, the composition comprising a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, and a pharmaceutically acceptable carrier or excipient.
Also provided is a method of treatment of osteoclast mediated bone degradation in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided is a method of treatment of cancer of the bone in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided is a method of treatment of cancer metastases to the bone in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof. Additional methods include those specifically to cancers of the bone that originate as, and are metastatic from, cancers of the breast, prostate, lung, kidney, thyroid, bladder, esophagus, stomach, liver, pancreas, testicles, skin, head and neck, lymphomas, multiple myelomas, and sarcomas from the soft tissue or bone.
Also provided is a method of treatment of cancer of the bone, or a cancer metastasis to the bone, in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, and a second therapeutic agent, such as, but not limited to, a hormone therapeutic agent or a chemotherapeutic agent. In specific, non-limiting embodiments, the hormone therapeutic agent can be an antiestrogen (e.g., tamoxifen, toremifene, fulvestrant, raloxifene, droloxifene, idoxifene and the like), progestogens (e.g., megestrol acetate and the like) aromatase inhibitors (e.g., anastrozole, letrozole, exemestane, vorozole, exemestane, fadrozole, aminoglutethimide, exemestane, l-methyl-l,4-androstadiene-3,17-dione and the like), anti androgens (e.g., bicalutimide, nilutamide, flutamide, cyproterone acetate, and the like), luteinizing hormone releasing hormone agonist (LHRH Agonist) (e.g., goserelin, leuprolide, buserelin and the like); 5-.alpha. -reductase inhibitors such as finasteride. In specific, non-limiting embodiments, the cytotoxic chemotherapeutic agent can be (i) alkylating agents, such as procarbazine, ifosphamide,
cyclophosphamide, melphalan, chlorambucil, decarbazine, busulfan, thiotepa, (ii) platinum
chemotherapy agents, such as cisplatin, carboplatin, oxaliplatin, Eloxatin, (iii) anti-metabolites, such as Methotrexate, 5-fluorouracil (e.g., capecitabine), gemcitabine (2'-deoxy-2',2'-difluorocytidine monohydrochloride (.beta. -isomer), Eli Lilly), 6-mercaptopurine, 6-thioguanine, fludarabine, cladribine, cytarabine, tegafur, raltitrexed, cytosine arabinoside, (iv) anthracyclines, such as daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, adriamycin, bleomycin, mitomycin-C, dactinomycin, mithramycin, (v) taxanes, such as paclitaxel, docetaxel, Taxotere, Taxol, taxasm, 7-epipaclitaxel, t-acetyl paclitaxel, 10-desacetyl-paclitaxel, 10-desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7- epipaclitaxel, 7-N--N-dimethylglycylpaclitaxel, 7-L-alanylpaclitaxel .
Also provided is a method of treatment of osteoporosis in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof. In one embodiment, the subject in need of treatment of osteoporosis is a postmenopausal woman. In another embodiment, the subject in need of treatment of osteoporosis is a man with osteoporosis. Also provided is a method of prevention or inhibition of osteoporosis in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided is a method of treatment of glucocorticoid-induced osteoporosis in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided is a method of treatment of Paget's disease of the bone in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided is a method of treatment of osteogenesis imperfecta of the bone in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
Also provided are intermediate compounds of the formula:
Figure imgf000020_0001
ni is an integer selected from the group of 1, 2, 3, 4, 5, and 6. Further provided are compounds of the formula:
Figure imgf000021_0001
wherein:
Pi is an integer selected from the group of 1, 2, 3, 4, 5, and 6. Synthesis
Compounds as described herein may be prepared by methods known in the art. Specific examples of synthetic routes are presented. The method below for the preparation of 3-(4- fluorophenyl)-7-hydroxychroman-4-one (Compound A) may also be seen in U.S. 2016/0128973 Al.
Figure imgf000021_0002
Compound A may be converted to 2-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)acetic acid, Compound B, by methods described in Chemical & Pharmaceutical Bulletin, 39(10), 2681-90; 1991, as follows.
Figure imgf000022_0001
compound A may also be converted to the corresponding carbonate compound, 3-(4- fluorophenyl)-4-oxochroman-7-yl phenyl carbonate, Compound C, as follows at from 0°-RT (room temperature) for about an hour.
Figure imgf000022_0002
Zolendronic acid can be converted to 3-(3-amino-2-hydroxypropyl)-l-(2-hydroxy-2,2- diphosphonoethyl)-lH-imidazol-3-ium, Compound D, as follows.
Figure imgf000022_0003
To reduce the inorganic residues 1.1 eq of Na2C03 was used instead of saturated Na2C03 solution for quaternization [step-2] reaction and 3-(3-((tert-butoxycarbonyl)amino)-2-hydroxypropyl)-l-(2- hydroxy-2,2-diphosphonoethyl)-lH-imidazol-3-ium, Compound 9, synthesized from this reaction was de protected. This freshly prepared , Compound D, was used for the final amidation reaction without further purification.
Synthesis of (l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-21-hydroxy-2,16-dioxo-7,10,13- trioxa-3,17-diazahenicosane-21,21-diyl)bis(phosphonic acid) was then accomplished by the steps below. Synthesis of the three E compounds, (n=l), (n=2), (n=3), and (n=4) are accomplished with the corresponding starting materials:
Figure imgf000023_0001
CAS Reg. No. 1260092-46-3
10a: tert-butyl 3-(2-aminoethoxy)propanoate
Figure imgf000023_0002
CAS Reg. No. 756525-95-8
10b: tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propanoate
Figure imgf000023_0003
CAS Reg. No. 756525-95-8
10c: tert-butyl 3-(2-(2-aminoethoxy)ethoxy)propanoate
Figure imgf000023_0004
CAS Reg. No. 1286281-32-0
ferf-butyl 1 -amino-3,6,9, 12,15,18-hexaoxahenicosan-21 -oate
Figure imgf000024_0001
Figure imgf000024_0003
Step 4
Compound E (n=l)
Figure imgf000024_0002
(4-(3-(2-(2-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)acetamido)ethoxy)propanamido)-l- hydroxybutane-l,l-diyl)bis(phosphonic acid) - obtained as a white solid. Chromatographic purity qualitative by HPLC (% by area normalization) at wavelength (X2ionm) : 97.14%. By NMR: Complies (1H); by Mass: Complies [M+H]: 663
*H NMR (400 MHz, D20) d (ppm) 7.93 (1H, d, J = 8.9 Hz), 7.39-7.31 (2H, m), 7.19 (2H, t, J = 8.8 Hz), 6.84 (1H, dd, J = 9.0, 2.4 Hz), 6.65 (1H, d, J = 2.4 Hz), 4.80-4.72 (4H, m), 4.24 (1H, t, J = 7.4 Hz), 3.72 (2H, t, J = 6.2 Hz), 3.63 (2H, t, J = 5.2 Hz), 3.51 (2H, t, J = 5.3 Hz), 3.22 (2H, t, J = 6.8 Hz),
2.46 (2H, t, J = 6.2 Hz), 1.99-1.95 (2H, m), 1.85-1.83 (2H, m).
Compound E (n=2)
Figure imgf000025_0001
(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-17-hydroxy-2,12-dioxo-6,9-dioxa-3,13- diazaheptadecane-17,17-diyl)bis(phosphonic acid) - obtained as a white solid. Chromatographic purity qualitative by HPLC (% by area normalization) at wavelength (X2ionm): 92.35%. By NMR: Complies (1H); by Mass: Complies [M+H]: 707
*H NMR (400 MHz, D20) d (ppm) 7.90 (1H, d, J = 8.8 Hz), 7.34 (2H, t, J = 6.8 Hz), 7.18 (2H, t, J =
8.6 Hz), 6.81 (1H, d, J = 9.0 Hz), 6.63 (1H, s), 4.76-4.72 (4H, m), 4.21 (1H, t, J = 7.4 Hz), 3.75-3.72 (2H, m), 3.64-3.50 (8H, m), 3.21 (2H, t, J = 6.8 Hz), 2.50 (2H, t, J = 6.2 Hz), 1.98-1.95 (2H, m), 1.85-1.83 (2H, m).
Compound E (n=3)
Figure imgf000025_0002
(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-21-hydroxy-2,16-dioxo-7,10,13-trioxa-3,17- diazahenicosane-21,21-diyl)bis(phosphonic acid) - obtained as a white solid. Chromatographic purity qualitative by HPLC (% by area normalization) at wavelength (A2ion ): 95.59%. By NMR: Complies (1H); by Mass: Complies [M+H]: 751
*H NMR (400 MHz, D20) d (ppm) 7.78 (1H, d, J = 8.8 Hz), 7.22 (2H, t, J = 7.0 Hz), 7.05 (2H, t, J = 8.8 Hz), 6.69 (1H, d, J = 9.7 Hz), 6.52 (1H, d, J = 2.5 Hz), 4.63-4.61 (4H, m), 3.62 (2H, t, J = 6.5 Hz), 3.53- 3.48 (9H, m), 3.39 (2H, d, J = 5.3 Hz), 3.09 (2H, t, J = 6.7 Hz), 2.38 (2H, t, J = 6.4 Hz), 1.82- 1.78 (2H, m), 1.69-1.68 (2H, m).
Synthesis of Compounds G (n=l), H (n=2), and I (n=3) is accomplished by the reaction scheme below.
Figure imgf000026_0001
Compound G (n=l)
Figure imgf000027_0001
3-(3-(3-(2-(2-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)acetamido)ethoxy)propanamido)-2- hydroxypropyl)-l-(2-hydroxy-2,2-diphosphonoethyl)-lH-imidazol-3-ium- obtained as a white solid. Chromatographic purity qualitative by HPLC (% by area normalization) at wavelength (X2ionm): 98.37%. By NMR: Complies (1H); by Mass: Complies [M+H]: 759
*H NMR (400 MHz, D20) d (ppm) 8.82 (1H, s), 7.93 (1H, d, J = 8.9 Hz), 7.58 (1H, t, J = 1.8 Hz),
7.41 - 7.31 (3H, m), 7.18 (2H, t, J = 8.8 Hz), 6.84 (1H, dd, J = 9.0, 2.5 Hz), 6.66 (1H, d, J = 2.4 Hz), 4.72-4.70 (2H, m), 4.22-4.07 (4H, m), 3.73 (2H, t, J = 6.1 Hz), 3.64 (2H, t, J = 5.1 Hz), 3.50 (2H, t, J = 5.2 Hz), 3.41 - 3.39 (1H, m), 3.29-3.23 (1H, m), 2.50 (2H, t, J = 6.1 Hz).
Compound H (n=2)
Figure imgf000027_0002
3-(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-18-hydroxy-2,15-dioxo-6,9,12-trioxa-3,16- diazanonadecan-19-yl)-l-(2-hydroxy-2,2-diphosphonoethyl)-lH-imidazol-3-ium- obtained as a white solid. Chromatographic purity qualitative by HPLC (% by area normalization) at wavelength (A2ion ): 89.88%. By NMR: Complies (1H); by Mass: Complies [M+]: 803 *H NMR (400 MHz, D20) d (ppm) 8.83 (1H , s), 7.92 (1H , d, J = 8.9 Hz), 7.58 (1H , s), 7.43 (1H, s), 7.35 (2H, t, J = 7.0 Hz), 7.19 (2H, t, J = 8.7 Hz), 6.82 (1H, d, J = 9.0 Hz), 6.65 (1H, s), 4.68-4.65 (2H, m), 4.36-4.32 (1H, m), 4.22 (1H, t, J = 7.2 Hz), 4.13-4.10 (2H, m), 3.76 (2H, t, J = 6.0 Hz), 3.74-3.64 (6H, m),
3.63-3.59 (2H, m), 3.50-3.45 (1H, m), 3.41-3.38 (1H, m), 2.56 (2H, t, J = 5.9 Hz).
Compound I (n=3)
Figure imgf000028_0001
3-(l-((3-(4-fluorophenyl)-4-oxochroman-7-yl)oxy)-21-hydroxy-2,18-dioxo-6,9,12,15- tetraoxa-3,19-diazadocosan-22-yl)-l-(2-hydroxy-2,2-diphosphonoethyl)-lH-imidazol-3-ium- obtained as a white solid. Chromatographic purity qualitative by HPLC (% by area normalization) at wavelength ( 2ionm): 94.61%. By NMR: Complies (1H); by Mass: Complies [M+]: 847
*H NMR (400 MHz, D20) d (ppm) 8.84 (1H, s), 7.92 (1H, d, J = 8.8 Hz), 7.58 (1H, s), 7.44 (1H, s), 7.35 (2H, t, J = 7.1 Hz), 7.19 (2H, t, J = 8.8 Hz), 6.83 (1H, d, J = 9.0 Hz), 6.66 (1H, d, J = 2.4 Hz), 4.81-4.74 (6H, m), 4.72-4.69 (2H, m), 4.38 (1H, d, J = 11.2 Hz), 4.26-4.14 (1H, m), 4.13-4.11 (2H, m), 3.76 (2H, t, J = 6.1 Hz), 3.69 -3.58 (8H, m), 3.53 (2H, d, J = 5.3 Hz), 3.46-3.42 (1H, m), 3.35-3.30 (1H, m), 2.55 (2H, t, J = 6.0 Hz).
Synthesis of Compound L
Figure imgf000028_0002
Figure imgf000029_0001
Compound L
Compound L: (4-(3-(2-((((3-(4-fluorophenyl)-4-oxochroman-7- yl)oxy)carbonyl)(methyl)amino)ethoxy)propanamido)-l-hydroxybutane-l,l-diyl)bis(phosphonic acid)
Nosyl group protection was performed with PEG-1 followed by N-alkylation on 0.5 g scale and isolated 0.4 g of compound 3. Nosyl deprotection of compound 3 was accomplished on 0.4 g [PhSH (1 eq.) / K2C03 (2.5 eq.) / DMF / RT] scale. Work up followed by purification provided 0.14 g of desired compound 4. 0.7 g of compound 4 was isolated after two steps of PEG-1 on 2 g scale. Coupling of compound 4 with compound F was done on 0.25 g [F (1.1 eq.) / triphosgene (0.5 eq.) / DIPEA (2 eq.) / DCM / 0 °C / lh] scale. Work up followed by several purifications provided 0.11 g of desired compound 5. Tert-butyl deprotection followed by preparation Osu derivative (lnt-7) in 0.11 g [TFA / DCM / RT / 5h then N- hydroxy succinimide (1.5 eq.) / EDC.HCI (3.0 eq.) / DCM / 0°C to RT / 16h] scale. Work up provided 0.2 g of desired Osu derivative 7. Final coupling of Intermediate 7 with alendronic acid (compound H) was performed on 0.05 g [alendronic acid (1.7 eq.)/ KFICO3 (2.0 eq.)/ DMF/Water] scale, which was submitted for prep-FIPLC purification. Now analysis is underway. Final coupling of Intermediate 7 with alendronic acid (compound H) was performed on 0.350 g [alendronic acid (1.7 eq.)/ KFICO3 (2.0 eq.)/ DMF/Water] scale. - obtained as a white solid. Chromatographic purity qualitative by H PLC (% by area normalization) at wavelength (X2ionm) : 97.39%. By NMR: Complies (1H); by Mass: Complies [M+H] : 663
*H NMR (400 MHz, D20) d (ppm) 8.00 (1H, d, J = 8.5 Hz), 7.38 (2H, br s), 7.21 (2H, t, J = 8.5 Hz),
6.94 (2H, d, J = 11.7 Hz), 4.34 (1H, t, J = 7.9 Hz), 3.86 (2H, d, J = 6.0 Hz), 3.81-3.77 (2H, m), 3.73 (1H, br s), 3.59 (1H, br s), 3.26-3.21 (2H, m), 3.18 (1H, s), 3.06 (2H, s), 2.57 (2H, br s), 1.98-1.95 (2H, m), 1.86-1.83 (2H, m).
Synthesis of Compound M
Figure imgf000030_0001
O
Figure imgf000031_0001
Compound M
Compound M: (4-(2-(3-((((3-(4-fluorophenyl)-4-oxochroman-7- yl)oxy)carbonyl)(methyl)amino)propoxy)acetamido)-l-hydroxybutane-l,l-diyl)bis(phosphonic acid)
CBZ protection (Step-1) was performed on 5 g scale with 3-(methylamino)propanol (SM 1) followed by O-alkylation (Step-2), we have isolated 4.5 g of compound 5. CBZ deprotection (Step-2) of compound 5 was carried out on 4.5 g [Pd-C / H2 /MeOH / RT] scale to achieve 2.6 g of compound 6. A coupling reaction between amine intermediate 6 with triphosgene has been attempted on 500 mg [triphosgene (0.5 eq.) /NaHCOs/CI-hCh /DMF/H2O/ 0°C to RT] scale. SM remains unreacted even after 12 h. A coupling reaction between compound F with triphosgene has been attempted on 700 mg [triphosgene (0.5 eq.) /DIPEA/CH2CI2 /DMF/0°C to RT] scale, we have isolated 400 mg of compound 7. 0.380 g of compound 8 was obtained as crude after the 0.4 g [TFA/DCM] scale deprotection of Compound 7. Preparation of OSu derivative (compound 9) has been attempted in 0.38 g [N-hydroxy succinimide (1.5 eq.) / EDC.HCI (3.0 eq.) / DCM / 0°C to RT / 2h] scale. Work up provided 0.4 g of desired compound 9 as crude. Finally coupling reaction of compound 9 and alendronic acid has been performed on 0.4 g
[alendronic acid (1.7 eq.)/ KFICO3 (2.0 eq.J/DMF/F O/RT] scale. Crude LCMS suggested the formation of desire compound M which was purified by prep-FIPLC and isolated 0.66 g of final compound M. - obtained as a white solid. Chromatographic purity qualitative by H PLC {% by area normalization) at wavelength (X2ionm) : 99.00%. By NMR: Complies (1H); by Mass: Complies [M+FI]: 663
*H NMR (400 MHz, D20) d (ppm) 8.00 (1H, d, J = 8.6 Hz), 7.38-7.36 (2H, m), 7.22 (2H, t, J = 8.8 Hz), 6.97-6.93 (2H, m), 4.35 (1H, t, J=7.7 Hz), 4.10 (1H, s), 4.05 (1H, s), 3.70 (3H, br s), 3.52 (1H, br s), 3.31 (1H, br s), 3.20-3.17 (2H, m), 3.05 (1H, s), 2.02-2.00 (4H, m), 1.86-1.84 (2H, m).
Additional information is available in the article d Multifunctional Therapy Approach for Cancer: Targeting Rafl-Mediated Inhibition of Cell Motility, Growth, and Interaction with Microenvironment, Zhang et al., Molecular Cancer Therapeutics, 19(1), January 2020, pp. 39-51, which is incorporated herein by reference in its entirety.
Studies
KBU2046 does not interfere with the activity of chemotherapy
Chemotherapy is widely used in the treatment of androgen independent PCa, both docetaxel and cabazitaxel have been shown to prolong life (Tannock et al., N EnglJ Med 351, 1502-1512 (2004); Sweeney et al., N EnglJ Med 373, 737-746 (2015); and Bono et al., Lancet 376, 1147-1154 (2010)), and both are taxanes that target microtubule function, thereby inhibiting cell growth ( Lyseng-Williamson et al., Drugs 65, 2513-2531, 2005). Combining chemotherapy with KBU2046 did not affect the ability of either docetaxel or cabazitaxel to inhibit the growth of androgen independent PC3-M cells in vitro (Fig. 1A).
A similar lack of interference upon cytotoxic action was also observed when KBU2046 was co administered with agents spanning different pharmacologic classes including, adriamycin, taxol and vinblastine, an effect demonstrated in both PC3-M cells and MDA-MB-231 human breast cancer cells. In order to evaluate whether KBU2046 would inhibit the efficacy of chemotherapy in vivo, mice were subcutaneously implanted with PC3-M cells and treated with docetaxel ± KBU2046 (Fig. IB). Compared to control mice, docetaxel significantly inhibited tumor growth (P<0.01). Flowever, KBU2046 did not significantly affect growth when added to control or docetaxel treated mice. These findings demonstrate that KBU2046 does not inhibit the efficacy of cytotoxic agents.
Figure 1 demonstrates KBU2046 does not inhibit chemotherapy efficacy against prostate cancer. Figure 1A depicts the effect of chemotherapy on the growth of androgen independent PC3-M PCa cells in vitro. Data are the mean ± SEM (N = 3 replicates) of cell viability in a 3 day growth assay in the presence of 10 mM KBU2046 or vehicle (control) treated with docetaxel or cabazitaxel. Figure IB depicts the effect of chemotherapy on the growth of androgen independent PCa cells in vivo. Mice received subcutaneous implants of PC3-M cells, were monitored until tumors were detectable (250 mm3), and then treated daily with oral 80 mg KBU2046/kg (46) or vehicle (CO) and with weekly intraperitoneal docetaxel (doc) at 0 or 20 mg/kg, beginning on day 1, and tumor size measured. Data are mean ± SEM, with N = 20 mice per cohort.
Combining anti-motility therapy with cytotoxic therapy has improved efficacy
Unregulated cell growth and unregulated cell movement constitute two elemental processes of cancer. A therapeutic strategy wherein both of these processes are targeted is rationally-based. We sought to examine if the combination of docetaxel plus KBU2046 would achieve the sustained inhibition of tumor growth kinetics of docetaxel while providing for improved antimetastatic efficacy, as compared to either agent alone. The PC3-M orthotopic implantation murine model allows for the quantification of primary tumor growth, the assessment of distant metastasis to the lungs, and has previously been used to measure the effects of therapy and genetic alterations on metastasis (Xu et al., Nature
Communications 9, 2454 (2018); Pavese et al., PLoS One 9, el02289 (2014); and Lakshman et al., Clin Exp Metastasis 28, 39-53 (2011)).
To assess the efficacy of a spectrum of docetaxel concentrations, mice received orthotopic implants of PC3-M-luc cells, were treated with 0, 10 or 20 mg/kg docetaxel, and tumor growth monitored with weekly IVIS imaging. Docetaxel significantly inhibited growth compared to controls in a dose-dependent manner. Subsequently, mice with orthotopic implants of PC3-M-luc cells were treated with docetaxel, KBU2046, docetaxel+KBU2046 or vehicle, as denoted, and effects on primary tumor growth and lung metastasis quantified (Figs. 2A, 2B, and 2C). Prior studies demonstrated that it is possible to detect as few as 10 human cells per mouse organ, i.e. kidney, using human Alu element- specific qPCR ( Funakoshi et al., Sci Rep 7, 13202 (2017)). We demonstrate that there is a linear relationship between number of PC3-M-luc cells present in mouse lung and qPCR-based detection of human Alu elements (Pearson R2 = 0.96). Using human Alu element-specific qPCR to quantify PC3-M-luc metastasis to lungs, we demonstrated that docetaxel, KBU2046 and docetaxel+KBU2046 decreased metastasis by 23% (P < 0.05), 20% (P < 0.05) and 48% (P < 0.001), respectively, compared to control mice. Of note, the combination of these two differentially acting agents achieved a significantly greater decrease in metastasis than that observed with either docetaxel (P < 0.05) or KBU2046 (P < 0.01) alone (Fig. 2A). Based upon the effect of each treatment alone, the calculated combined effect of
docetaxel+KBU2046 is 42% reduction, giving an experimental/calculated ratio of 1.1, or additive-to- slightly-synergistic.
Evaluation of prostate tumor growth by weekly IVIS imaging demonstrated exponential growth kinetics in cohorts not receiving docetaxel, and slower growth in cohorts receiving docetaxel (Fig. 2B). Measurement of actual tumor weight demonstrated that docetaxel and docetaxel+KBU2046 decreased tumor weight by 49% (Fisher's exact P < 0.05) and 37% (Fisher's exact P < 0.05), respectively, compared to control (Fig. 2C). KBU2046 as a standalone agent had no significant effect, nor did it significantly impair docetaxel's efficacy. These findings demonstrate that combining anti-motility therapy with cytotoxic therapy allows dual targeting of cell growth and cell movement, resulting in sustained control of primary tumor growth and enhanced control of metastatic disease progression.
Figure 2 demonstrates that KBU2046 plus docetaxel exhibits increased anti-metastatic efficacy. Cohorts of N = 10 mice bearing orthotopic implants of PC3-M-luc cells were treated daily with 150 mg/kg KUB2046 (46), intraperitoneal docetaxel 7.5 mg/kg weekly (doc), the combination (doc+46), or with oral and intraperitoneal vehicle (CO). KBU2046 treatment began 3 days before implantation and docetaxel began 1 week after. (A) Lung metastasis measured by qPCR for human Alu sequences, expressed as percent control (B) Weekly I VIS imaging of tumor. (C) Tumor weight. *denotes P < 0.05 for differences between cohorts denoted by bars. All data are mean ± SEM.
KBU2046 does not interfere with hormone therapy
Hormonal therapy is the mainstay of treatment for metastatic PCa ( N. C. C. Network, Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Version 4, (2018)). It is therefore important to ensure other therapeutic modalities do not interfere with it. Initial hormone treatment involves decreasing testicular androgen production, and is termed androgen deprivation therapy (ADT). Disease progression, which is inevitable, is termed castrate-resistant PCa, and is commonly treated with an androgen receptor (AR) antagonist, such as enzalutamide (Beer et al., N Engl J Med 371, 424-433 (2014)). To evaluate KBU2046's effect upon this paradigm investigations began with the androgen sensitive LNCaP and VCaP human PCa cells, which have been well characterized for their response to hormonal targeted therapies (Furr et al., Eur Urol 29 Suppl 2, 83-95 (1996) 23; and Tran et al., Science 324, 787-790 (2009)).
Cells were cultured in media depleted of androgen and after a washout of 72 hrs were treated with the synthetic androgen R1881, KBU2046, enzalutamide and/or vehicle (control), and resultant effects upon induction of the androgen-responsive gene, prostate specific antigen (PSA) were measured (Fig. 3A). In both cell lines, R1881 significantly increased PSA expression and enzalutamide decreased it. In LNCaP cells, KBU2046 had no significant effect. In VCaP cells, KBU2046 significantly decreased PSA expression in R1881 treated cells by 36% (P<0.05). While it also significantly increased expression in control cells (P<0.05), absolute baseline levels were very low and the relative increase was only 14%. Evaluating effects on cell growth, enzalutamide significantly inhibited it compared to controls (P<0.05) in both LNCaP and VCaP cells, whereas the addition of KBU2046 to either control or enzalutamide treated cells had no significant effect (Fig. 3C and 3D).
Several considerations warranted a deeper examination of the effect of KBU2046 on AR function. In VCaP cells KBU2046 significantly inhibited R1881-mediated PSA gene expression, consistent with inhibition of AR function. Additionally, AR is a client protein of HSP90, AR function requires HSP90- mediated chaperone action, and direct inhibitors of HSP90 decrease client protein expression and inhibit AR function (24-26 Fang et al., J Biol Chem 271, 28697-28702 (1996); Saporita et al., Prostate 67, 509- 520 (2007); and Ni et al., Mol Cell Biol 30, 1243-1253 (2010)). KBU2046 is not a direct inhibitor of HSP90, and as such does not globally decrease client protein expression. It is a selective FISP90 activity modulator (SFIAM), and selectively modulates client proteins that regulate cell motility. Flowever, the effect of KBU2046 on AR expression and function had not been examined. After ligand binding, functional AR translocates from the cytoplasm to the nucleus, and nuclear localization therefore provides a measure of functional AR. By treating LNCaP and VCaP cells with R1881, KBU2046, and/or enzalutamide, and measuring AR expression by Western blot in resultant nuclear and cytoplasmic cellular fractions, we demonstrated that KBU2046 did not affect AR expression or nuclear localization in response to R1881, nor its inhibition by enzalutamide (Fig. 3E).
To complete our assessments of the androgen related paradigm, the effect of KBU2046 on resistance to hormone therapy was evaluated. The outgrowth of LNCaP/AR-luc cells in castrate mice is routinely utilized as a model to emulate the transition to a castration resistant phenotype (Tran et al., Science 324, 787-790 (2009)). In this model, tumor outgrowth is detectable ~8 weeks post implantation, and growth kinetics are typically monitored until 16 weeks post implantation. Flere, two treatment approaches were investigated, the effects of beginning treatment early at 4 weeks, or late at 12 weeks, and were performed in mice receiving subcutaneous or orthotopic implants, respectively (Figs. 3F and 3G). KBU2046 did not alter tumor growth in either model. Taken together, these findings support the notion that KBU2046 does not affect androgen signaling, nor does it inhibit the efficacy of ADT or of AR antagonist therapy.
Figure 3 helps demonstrate that KBU2046 also does not affect androgen signaling nor therapeutic targeting. LNCaP or VCaP cells cultured in hormone free media were treated with R1881 (R), KBU2046 (46) and/or enzalutamide (E). (A and B) Effects on AR-responsive gene expression. PSA expression was measured by qRT/PCR, normalized to GAPDH and expressed as a percent of control cells (N=3 replicates); * denotes P < 0.05 for groups separated by bar. (C and D) Effects on cell growth. Three day growth assays were performed. Data are the number of viable cells, expressed as % of control (N=3 replicates); * P < 0.05 compared to control. (E) Effects on AR activation. Western blots of nuclear (N) and cytoplasmic (C) preparations of cell extracts were probed for AR, laminin B1 or a-tubulin. (F andG)
Effects on tumor outgrowth after androgen deprivation therapy. LNCaP/AR-luc cells were implanted subcutaneously (N=6 mice/cohort) or orthotopic (N=15 mice/cohort were implanted; N=5 yielded tumors) into castrate mice, treatment with KBU2046 began as noted, and weekly IVIS imaging performed. Data are tumor size, expressed as luminescence intensity. All data are expressed as mean ± SEM.
Combining anti-motility therapy with therapy directed at the bone microenvironment has improved efficacy
Metastasis to the bone occurs in over 90% of people with metastatic PCa (Polascik, Ther Clin Risk Manag 4, 261-268 (2008)). Upon arrival to bone, PCa cells modify the environment in a manner conducive to their outgrowth engaging what is known as the "vicious cycle" (Guise, J Musculoskelet Neuronal Interact 2, 570-572 (2002); Guise et al., Endocr Rev 19, 18-54 (1998); and C. Logothetis et al., Cancer Metastasis Rev 37, 189-196 (2018)). Specifically, PCa cells secrete interleukin (IL)-ll and parathyroid hormone-related protein (PTHrP), stimulating osteoblasts to secrete receptor activator of nuclear factor kappa-B ligand (RANKL), RANKL induces osteoclasts to degrade bone, degradation of bone matrix releases insulin growth factor (IGF) and transforming growth factor (TGF) , which act to sustain PCa cell growth. We previously demonstrated that KBU2046 inhibits cell motility by inhibiting activation of Rafl, specifically, by inhibiting phosphorylation of its Ser338 activation motif (Xu et al., Nature Communications 9, 2454 (2018)). A central function of Rafl relates to regulating reorganization of the actin cytoskeleton, which in turn affects how cells interact with and move through the
microenvironment (Yotova et al., J Cell Mol Med 16, 2127-2139 (2012)). Cytoskeleton reorganization is required for osteoclasts to successively move across and to bind bone matrix, doing so by arranging their actin cytoskeleton to form a low pH resorptive cavity in which degradation of bone mineral occurs (Florencio-Silva et al., Biomed Res Int 2015, 421746 (2015)). These facts led us to consider that osteoclast-mediated bone degradation was dependent upon cytoskeleton reorganization, and therefore might be inhibited by KBU2046.
To examine this paradigm we first evaluated whether KBU2046 would inhibit Rafl
phosphorylation in osteoclasts. After treatment with RANKL, RAW 267.4 cells differentiate into mature osteoclasts. Upon maturation osteoclast become multinucleated, express tartrate resistant acid phosphatase (TRAP), and have the capacity to form actin rings that create an occluded cavity in which bone is degraded. KBU2046 inhibits phosphorylation of Rail's activation motif in RANKL treated RAW 267.4 osteoclast cells, and does so in a time-dependent manner (Fig. 4A). In osteoclasts Rail is known to phosphorylate MEK1/2, in turn phosphorylating ERK1/2 (Bradley et al., J Cell Biochem 104, 1439-1451 (2008)), with the latter acting to stimulate osteoclast differentiation and bone resorptive activity ( He et al., PLoS One 6, e24780 (2011); and Nakamura et al., J Bone Miner Res 18, 1198-1205 (2003)). The functional relevance of KBU2046-mediated inhibition of Rail phosphorylation is shown by
demonstrating inhibition of MEK1/2 and ERK1/2 phosphorylation. Osteoclasts in Fig. 4A were not cultured on bone mineral, demonstrating that KBU2046-mediated inhibition of Rafl phosphorylation is not dependent upon the presence of bone mineral.
Treatment of RAW 267.4 cells with KBU2046 induces several structural and functional changes. It reduces RANKL-mediated formation of multinucleated cells, and those that do form have lower numbers of nuclei (see 40x panels, Fig. 4B). The characteristic prominent actin ring (white arrow) surrounding the resorptive cavity (yellow arrow) is readily apparent in control cells treated with RANKL ligand, but is lacking in KBU2046-treated cells (100*, panels). Consistent with it inhibiting maturation of RAW 267.4 cells, TRAP staining is decreased in KBU2046-treated cells (Fig. 4C). In the absence of RANKL, undifferentiated RAW 267.4 cells exhibit a phenotype characterized by isolated cells with long thin cytoplasmic extensions (Fig. 4B). However, treatment with KBU2046 markedly reduces cellular extensions, demonstrating that its ability to induce effects on RAW 267.4 cells is not RANKL dependent.
Figure 4 represents the KBU2046 inhibition of osteoclast function. Figure 4A compares effects on Rafl activation. RAW 267.4 cells were treated with RANKL for 4 days, treated with 10 mM KBU2046 for the indicated time periods, and Western blot for the denoted proteins performed. (B) Effects on cell morphology. RAW 267.4 cells were treated with RANKL and with KBU2046 for 4 days, or not, and denoted, and stained for actin (green) and DAPI (blue); white arrow denotes an actin ring, yellow arrow a resorptive cavity. Representative immunofluorescent images are depicted. (C) Tartrate resistant acid phosphatase (TRAP) expression. Cells were treated as in B, stained for TRAP (denoted by presence of red), and representative images from light microscopy depicted. (D) Bone degradation. RAW 267.4 cells were plated onto Osteo Assay plates, treated with RANKL for 6 days and with KBU2046 (or vehicle for controls) as indicated and bone surface area quantified. Data are the mean ± SEM (N=3 replicates) of bone surface area, expressed as the percentage of control cells; *denotes P < 0.05 compared to control. To determine whether KBU2046 inhibits osteoclast-mediated bone degradation, we used Corning Osteo Assay Surface plates, which are coated with calcium-phosphate-based bone mineral. This platform supports osteoclast growth, allowing for the quantitative measurement of bone degradation, and has previously been used to measure bisphosphonate-mediated inhibition of bone degradation (40). RAW 267.4 cells were grown on Osteo Assay plates in the presence of RANKL, treated with KBU2046 at 1 pmol/L, 10 pmol/L, orwith vehicle (control), and effects on bone destruction quantified after 6 days. In this manner we demonstrated that when 10 pmol/L KBU2046 is present, it significantly increased bone surface area by 28% ± 1.4% (mean ± SEM) compared with control (P < 0.05; Fig. 4D). To further substantiate the role of Raf1 , we demonstrate in Supplementary Fig. S5 that each of the Raf1 -specific inhibitors, ZM336372, GW5074, and NVP-BHG712, inhibit osteoclast- mediated bone degradation, as well as RANKL-induced osteoclast maturation. The latter is demonstrated by decreased TRAP staining, decreased formation of multinucleated cells, and inhibition of resorptive cavity formation. Together, these findings demonstrate that we can inhibit degradation of bone matrix through an innovative strategy targeting Raf1 .
We next examined targeting of the bone microenvironment coupled to targeting cell motility. Bisphosphonates modify the bone microenvironment by chemically binding to calcium-phosphate bone mineral, are then taken up by osteoclasts after they digest the bound mineral and once inside the cell, they inhibit osteoclast-mediated bone degradation (Polascik et al., Ther Clin Risk Manag 4, 261-268 (2008)). The bisphosphonate, zoledronic acid (ZA), is used clinically to decrease bone fractures in men with metastatic PCa (Saad et al., J Natl Cancer Inst 94, 1458-1468 (2002); Saad et al., J Natl Cancer Inst 96, 879-882 (2004); and James et al., JAMA Oncol 2, 493-499 (2016) ). ZA is administered to humans by injection, whereupon it binds to bone mineral, while the remainder is rapidly cleared from the body, and that bound to bone mineral is responsible for inhibition of osteoclast activity and resultant decrease in bone fractures in men with metastatic PCa (N. Pharmaceuticals, Zoledronic Acid package insert FDA approved drug package insert, (2007)). We therefore focused our investigations upon ZA. Further, we emulated the pharmacologic situation in humans by pre-treating Osteo Assay plates with ZA, washing non-bound ZA away prior to adding RAW 267.4 cells, then treated, or not, with KBU2046, and measured resultant effects upon bone degradation. ZA was evaluated at 2, 10 and 20 mM, demonstrating a concentration dependent increase in bone surface area, all significant compared to control (P < 0.05) (Figs. 5A and 5B). KBU2046 similarly significantly increased bone surface area (P < 0.05). Importantly, the combination of ZA+KBU2046 yielded significantly improved efficacy compared to either agent alone (P < 0.05), did so with all ZA concentrations tested, and with the combination of 20 pM ZA+KBU2046 bone surface area increased to 193 ± 1.6% of control (mean ± SEM). When combined with KBU2046, upon going from 10 to 20mM ZA, there was no further improvement in efficacy, consistent with a plateau effect.
Figure 5 represents the improved efficacy seen with KBU2046 combined with ZA. In Figure 5A bone degradation was tested using osteo assays performed as in Figure 4D. Cells were treated with KBU2046 (46), ZA at 2, 10 or 20 mM, with the indicated combinations, or vehicle (control; CO). Data are the mean ± SEM (N=3 replicates); *denotes P < 0.05 compared to control, or between conditions denoted by bars. Figure 5B provides representative photomicrographs of osteo assay wells. Black color denotes presence of bone matrix; RL: RANKL. (C-E) Cell viability, cytotoxicity and apoptosis. RAW 267.4 cells were treated with RANKL, at day 4 they were treated with KBU2046, ZA at 1 or 10 mM (ZA1 or ZA10), the indicated combination, or vehicle (CO) and Triplex assay performed 24, 48 or 72 hours later, per Methods. Data are the mean ± SEM (N=4 replicates); ¥, #, *denotes P < 0.05 compared to control. (F-H) In vivo efficacy. Four cohorts of mice, N=15/cohort, were given intracardiac injections of PC3-luc cells, yielding the following successful injections: N=12 control, N=12 ZA, N=13 KBU2046 and N=13 ZA+KBU2046. Treatment was oral 150 mg KBU2046/kg daily (starting 3 days before 1C injection), intraperitoneal ZA 100 pg/kg weekly (starting 1 week before 1C injection), with oral and intraperitoneal vehicle controls given as indicated. (F) Representative computed tomography images. Image types are: side view and coronal sections of skull, and axil and sagittal sections of the femurs. Red arrows denote areas of bone destruction. (C and D) Quantification of bone lesions. The macroscopic lesions in the jaw were quantified by direct measurement from CT images, and expressed as the mean ± SEM percent of control. Bone density of femurs was measured from CT images, and expressed as the mean ± SEM percent of control. *denotes P < 0.05 compared to control, and for groups indicated by bars.
We next examined the effect of ZA and KBU2046 on osteoclast cell viability, apoptosis and cytotoxicity. RAW 267.4 cells were treated with RANKL for the duration of the experiment, at day 4 they were then treated with ZA, KBU2046, the combination, or vehicle (for controls), and effect on cell viability, apoptosis and cytotoxicity measured by T riplex assay at 24, 48 and 72 hours after treatment (Figs. 5C-E). In each of Figures 5C, 5D, and 5E, the sequence of bars in each of the three clusters of bars, from left to right, is control, KBU2046, ZA1, ZA10, ZA1+46, and ZA10+46.
It is important to consider that during the 7 day time course of this experiment, RAW 267.4 cells, under the influence of RANKL, are undergoing maturation to terminally differentiated osteoclasts.
Findings in control cells are consistent with this process, demonstrating successive decreases in cell viability, accompanied by increases in cellular cytotoxicity and apoptosis with time. Findings with KBU2046 are consistent with it delaying the maturation process, and include significant increases in cell viability and decreases in cytotoxicity at 72 hours, compared to control (P < 0.05). There is a notable significant increase in apoptosis in KBU2046 treated cells at 72 hours compared to controls (P < 0.05), possibly reflecting prior findings by other investigators linking suppression of Rafl signaling to an increase in apoptotic activity (Alejandro, J. D. Johnson, Inhibition of Raf-1 alters multiple downstream pathways to induce pancreatic beta-cell apoptosis. J Biol Chem 283, 2407-2417 (2008)). The combination of ZA+KBU2046 significantly increased apoptosis and cytotoxicity at 48 hours, but there was little-to-no effect on viability at 72 hours.
To evaluate the effectiveness of this strategy in vivo, we used the human PC3-luc PCa intracardiac injection model (Xu et al., Nature Communications 9, 2454 (2018); and Chu et al., Mol Cancer Res 6, 1259-1267 (2008)). In this model, mice develop widespread metastasis to the bone, with those to the mandible being the most prominent and symptomatic. Mice were treated with either ZA, KBU2046, ZA+KBU2046 or vehicle (control), and at the end of the experiment CT images of the bones were obtained and metastasis to the mandible and femur quantified (Figs. 5F-H). Weekly I VIS imaging demonstrated progressive tumor growth over the five weeks of the experiment in the mandible, femur and whole body, across all cohorts of mice. Representative CT images demonstrate the typically large destructive lesions in the mandible (Fig. 5F), and these were quantified by direct measurement (Fig. 5G). Metastasis to the femur were smaller, led to generalized loss of bone, with representative images demonstrating decreased density of trabecular bone and thinning of cortical bone (Fig. 5F), and were quantified by measurement of density (Fig. 5H). In the mandible, KBU2046 inhibited bone destruction by 33 ± 4.2% (P < 0.05) compared to control. While ZA also decreased bone destruction, this effect was not significant. Importantly, ZA did not impair KBU2046 efficacy. In the femur, bone density was significantly (P < 0.05) improved as compared to control by 56 ± 2.7% and 22 ± 2.4% with ZA or KBU2046 treatment, respectively. Further, the combination of ZA+KBU2046 resulted in significant (P < 0.05) additive efficacy compared to either standalone treatment, significantly increasing density by 76 ± 3.7% as compared to the control treatment cohort. Together, these findings demonstrate that combined targeting of cell motility and the bone microenvironment has additive therapeutic efficacy, an effect observed across both in vitro and in vivo model systems.
Increased cell motility and resultant metastasis is the process by which the vast majority of solid tumor cancers cause death (Minn, J. Massague, in CANCER: Principals and Practice of Oncology, V. T. DeVita, T. S. Lawrence, S. A. Rosenberg, Eds. (Lippincott Wiliams & Wilkins, New York, 2008), pp. 135- 146; and Seyfried et al., Crit Rev Oncog 18, 43-73 (2013)). Considering all forms of cancer, metastasis is responsible for over 90% of mortality (40), and for PCa it is responsible for essentially 100% (41, 42 Norgaard et al J Urol 184, 162-167 (2010); and Pound et al JAMA 281, 1591-1597 (1999)). Despite the overwhelming importance of this process, there remains limited therapeutic options available to patients. With KBU2046 and its ability to serve as a SHAM agent, selectively inhibiting Rafl activation, precision targeting of cell motility and resultant metastasis is now possible.
Increased cancer cell motility is a characteristic of cancer which represents a clinically relevant driver of morbidity and mortality, and constitutes an important therapeutic target that we can now access. As such, we believe it is centrally important to consider it as one of several abnormal functions.
In this regard, two criteria become apparent. First, this new found therapeutic capability cannot mitigate the efficacy of established clinical agents. Second, it underscores the strategic importance of treating cancer in a manner that targets multiple functions. Such an approach constitutes multi-functional therapy. This concept should not be confused with multi-modality therapy. The latter uses multiple therapies directed at different targets and/or pathways, but which relate to a similar set of cellular functions, such as growth and or viability.
We herein demonstrate for the first time that anti-motility therapy can be deployed in a combined non-interfering manner with multiple classes of agents previously established to have efficacy in humans. Specifically, we demonstrate sustained efficacy in conjunction with several differentially acting cytotoxic chemotherapeutic agents, and do so in cell culture based studies as well as in two murine models, one utilizing subcutaneous and one utilizing orthotopic implantation. In the case of ZA, an agent that modifies the bone microenvironment, we also demonstrate that anti-motility therapy does not interfere with its activity. If fact we demonstrate that it enhances it. Here too, experiments spanned cell culture based and human murine xenograft based models of bone destruction.
Additionally, we demonstrated that anti-motility therapy does not interfere with therapies that target the androgen axis. Again, studies involved cell culture models, as well as murine models of
subcutaneous and orthotopic implantation. Studies were performed in the context of androgen deprivation therapy and androgen receptor antagonist therapy, examining the effects upon cell and tumor growth, androgen-responsive gene activation and androgen receptor activation. Finally, it is important to consider that these findings taken together serve to provide additional evidence of the selective nature of KBU2046 and its mechanism of action.
After demonstrating that anti-motility therapy did not inhibit the efficacy of established therapy, we went on to demonstrate its applicability in the context of multi-functional therapy. Specifically, we demonstrated that the combination of docetaxel + KBU2046 not only retained the growth inhibitory efficacy of docetaxel but also exhibited additive efficacy at inhibiting metastasis. Docetaxel is a cytotoxic chemotherapeutic agent that inhibits cell growth and induces cell death through apoptosis, and is widely used across several cancer types inclusive of PCa. Such a strategic approach would be applicable to existing clinical scenarios where docetaxel is used to treat PCa, especially in the newly diagnosed metastatic setting, where the combination would serve to decrease formation of secondary metastasis. Because robust pre-clinical systemic models of the formation of metastasis as a function of targeting the androgen axis are lacking, we have not demonstrated that KBU2046 would provide additive
antimetastatic efficacy when combined with hormone therapy. However, existing data supports that the use of KBU2046 along with hormone therapy would further decrease the development of metastasis. Specifically, we have previously demonstrated that KBU2046 will inhibit the motility of androgen- responsive PCa cell lines (Xu et al, above). Further, KBU2046 did not interfere with AR antagonist therapy mediated by enzalutamide, a widely used agent shown to decrease metastasis in humans (Hussain et al., N EnglJ Med 378, 2465-2474 (2018)).
We also demonstrated that anti-motility therapy can enhance the efficacy of bone
microenvironment targeting agents such as ZA. Osteoclasts modify the bone microenvironment in manner that requires them to interface with the bone mineral surface and to reorganize their actin cytoskeleton in order to form a chamber whose function is to degrade bone. Given that Rafl is a known regulator of this process (Bradley et al., J Cell Biochem 104, 1439-1451 (2008); He et al., PLoS One 6, e24780 (2011); and Nakamura et al., J Bone Miner Res 18, 1198-1205 (2003)), we hypothesized that KBU2046 mediated inhibition of Rafl phosphorylation on its activation motif would inhibit actin reorganization and as a result inhibit bone degradation. We demonstrated that this was the case, and did so evaluating bone degradation in vitro and with animal models of bone destruction. These findings represent a new mechanism and new strategic approach to inhibiting osteoclast function and bone destruction, and has wide spread implications.
Given that KBU2046 affects osteoclast motility and that ZA effects the bone microenvironment, i.e., separate but complementary mechanisms, we hypothesized that together they would have at least additive therapeutic efficacy at inhibiting osteoclast-mediated bone destruction. Our findings directly supported this concept. Specifically, our in vitro model system of osteoclast-mediated bone destruction demonstrated additive effects of the two agents over a spectrum of ZA concentrations. A combined targeting approach was also supported by our findings with the murine model of human PCa mediated bone destruction, where we observed two forms of additive efficacy. In the femur, the combination of both agents gave additional efficacy when compared to either agent alone. The other form of additive efficacy relates to anatomic site. In the mandible, KBU2046 exhibited high efficacy whereas ZA exhibited none. In the femur, ZA was highly efficacious, and while KBU2046 was also efficacious, it was much less than ZA. It will be important in future studies to understand the mechanistic underpinnings of these anatomic differences in agent efficacy. It is interesting to note that the use of ZA is associated with osteonecrosis of the jaw in humans. While the biology of this is poorly understood, and pre-clinical models are currently lacking, current findings support the speculation that ZA's inability to provide protection in the jaw. Given that co-administration of KBU2046 and ZA leads to additive efficacy even at low ZA concentrations and that each agent elicits site specific effects, a multi-functional therapy approach may provide a platform to scale back ZA dosing, minimizing the potential for osteonecrosis while retaining protection against bone related events.
In summary, we demonstrated that a novel anti-motility agent, bisphosphonate-linked- KBU2046, can effectively be combined with other targeted functional therapies for cancer. Such an approach addresses the paradigm of cancer arising from a relatively wide set of dysfunctions that together constitute characteristics of cancer. Such an approach is associated with improved efficacy across several clinically relevant models, and together support the translation of this approach into human studies.
MATERIALS AND METHODS
Experimental Design
These investigations were designed to determine whether treating cancer with targeted multi functional therapy, involving inhibition of cell motility, provided added therapeutic efficacy compared to existing therapies that targeted different cancer-relevant functions. Cell motility was inhibited with KBU2046, cell growth and viability were inhibited with several types of cytotoxic chemotherapy agents, including docetaxel, taxol, vinblastine and Adriamycin, or with hormone therapy, including androgen deprivation or enzalutamide, and the bone microenvironment was modified with zoledronic acid. The effects of combining KBU2046 and individual chemotherapy agents on cell growth were measured by cell growth inhibition assays performed on a panel of human cancer cell lines. The effects upon tumor growth were measured in athymic mice given PC3-M cells subcutaneous implants. The effects upon tumor growth and formation of metastasis were measured in athymic mice given orthotopic implants of PC3-M cells, and measuring primary tumor growth and quantifying metastasis to the lungs. The effects of hormone therapy on cell growth and PSA expression were measured on LNCaP or VCaP cells grown in vitro, while effects on tumor growth evaluated LNCaP-AR cells implanted either subcutaneously or orthotopically. The ability of KBU2046 and ZA to inhibit bone destruction was measured by adding osteoclasts to Osteo-Assay plates, and measuring pit formation. Inhibition of bone destruction in athymic mice was measured by CT scan of animals after intracardiac injection of PC3 cells. Inhibition of Rafl phosphorylation in osteoclasts was measured by Western blot, while changes in the actin cytoskeleton and cell morphology were measured by immunofluorescent microscopy.
Cells culture and reagents
The following prostate cancer cells lines, PC-3, LNCaP, and VCaP were obtained from American Type Culture Collection, the constitutively active luciferase expressing PC3-Luc cell line was obtained from PerkinElmer, the origin a characteristics of PC3-M cells have been previously described by us (Liu et al., Prostate cancer and prostatic diseases 4, 81-91 (2001)). The constitutively active luciferase expressing PC3-M-luc cell line was established by transducing the parental cell line with pGL4.50 luciferase reporter (Promega), and culturing under hygromycin selection for stable integration. The LNCaP/AR-luc cell line was kindly provided by Charles Sawyers (Tran et al, Science 324, 787-790 (2009)).
The osteoclasts precursor mouse macrophage cell line Raw 264.7 was obtained from American Type Culture Collection. All cells were cultured as previously described ( Xu et al. above; Liu et al., Prostate cancer and prostatic diseases 4, 81-91 (2001); and Korenchuk et al., In Vivo 15, 163- 168 (2001), were maintained at 37°C in a humidified atmosphere of 5% carbon dioxide with biweekly media changes. All cell lines were drawn from stored stock cells, and replenished on a standardized periodic basis and were routinely monitored for Mycoplasma (PlasmoTest™, InvivoGen, San Diego, CA). Cells were authenticated by the following: they were acquired from the originator of that line, grown under quarantine conditions, expanded and stored as primary stocks and not used until following conditions were met: mycoplasma negative; through morphologic examination; growth characteristics; hormone responsiveness or lack thereof. KBU2046 was synthesized as previously described (5).
Enzalutamide (#S1250), docetaxel (#S1148) and zoledronic acid (#S1314) were purchased from
Selleckchem, and reconstituted per the manufacturer's recommendations.
Cytotoxicity assays and colony formation assays
To assess the impact of cytotoxic chemotherapy on PCa growth kinetics seven-day soft agar colony formation assays and three-day MTT cell growth inhibition assays were performed as described by us (Pavese et al., Cancer Lett 352, 179-186 (2014)). MTT assays were in replicates of N = 3, and were repeated, soft agar assays were in replicates of N=2 and are presented as mean number of colonies, expressed as percent of untreated controls.
Reverse transcription and quantitative PCR analysis
RNA was isolated and qRT/PCR performed as previously described by us ( Ding et al., J Biomol Tech 18, 321-330 (2007)). Resultant data were analyzed using the 2 DDa method ( Livak et al., Methods 25, 402-408 (2001)), normalized to GAPDH, for the following primer/probe sets (ABI) PSA
(Hs02576345_ml) and GAPDH (Hs99999905_ml). Assays were performed in triplicate, and were repeated.
Enzalutamide mediated cell growth inhibition assays
Enzalutamide mediated growth inhibition was assessed using Sulforhodamine B (SRB) growth inhibition assays, were performed as previously described (49). In brief, LNCaP and VCaP cells were pre incubated in charcoal-striped medium for 48 hours and then seeded (1.9 x 104) in 96-well plates. Cells were stimulated with 1.0 nM R1881 and treated for 72-hours with 10 mM KBU2046 or vehicle control in the presence or absence of 10 pM enzalutamide, and subsequently SRB assays were performed. Assays were in replicates of N=6, and were repeated.
Subcellular localization of Androgen receptor
LNCaP and VCaP cells were pre-incubated in the charcoal-striped medium containing 10 pM KBU2046 or vehicle control for 72 hours. Cells were then stimulated with 1.0 nM R1881 and treated for 24-hours with 10 pM KBU2046 or vehicle control in the presence or absence of 10 pM enzalutamide.
The nuclear and cytosolic subcellular fractions of the cells were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce, Waltham, MA) according to the manufacturer's instructions. Protein was quantified by BCA assay (Thermo-Fisher Scientific, Waltham, MA), per manufacturer's instructions.
Western blot analysis
Western blots were performed as described by us (Xu et al., Nature Communications 9, 2454 (2018); and Pavese et al., Cancer Lett 352, 179-186 (2014)). All Western blots were repeated at least once. Antibodies recognizing Androgen receptor (#5153S), Lamin B1 (#13435), and a-Tubulin (#3873) phospho-c-RAF (ser338) (#9427), c-Raf (#53745), MEK 1/2 (#12671), phospho-MEK 1/2 (#9121) , ERK 1/2 (#4695), phospho-ERK 1/2 (#4370), GAPDH (#2118), antimouse IgG-HRP linked secondary (#7076), and anti-rabbit IgG-HRP linked secondary (#7074) antibodies were purchased from Cell Signaling Technology. Pierce ECL western blotting substrate (#32106) and SuperSignal West Femto maximum sensitivity substrate (#34096) were purchased from Thermo Scientific. All primary antibodies were used at a dilution of 1:1000 and corresponding secondary antibodies used at a dilution of 1:5000.
Immunofluorescence
Dylight™ Phallodin (#12935) was purchased from Cell Signaling Technology.
Raw 264.7 cells were grown in differentiation medium (described below), with or without KBU2046, for 4 days on a Chamber Slide (Nunc Lab-Tek). Chambers were washed once with PBS, followed by 10-minute fixation in cold 10% neutral-buffered formalin (VWR) and a post-fixation wash with PBS. Permeabilization was achieved with incubation in 0.1% Triton X-100 (Sigma) for 5 minutes, and then blocked overnight at 4°C with 1% BSA (Sigma) containing 10% goat serum (Thermo Fisher
Scientific), 0.3 mol/L glycine (Sigma), and 0.1% PBS-Tween20. The cells were then incubated for 2 hours at 4°C in Dylight Phallodin (Cell Signaling technology, #12935) antibody diluted 1:40 in 1 c PBS with 1% BSA and 0.3% Triton X-100. Subsequently, the slide was washed once with PBS, a coverslip mounted with ProLong Gold Antifade Reagent with DAPI (Cell Signaling Technology, #8961), and imaged on a Confocal Microscope (Nikon/Yokogawa Spinning Disc).
Pit formation assays
Low passage (p < 4) RAW 264.7 cells were suspended in osteoclasts differentiation media (MEM- alpha (Gibco) with 10% FBS, 1% antibiotic-antimycotic and 50 ng/ml RANKL (EMD Millipore, R0525- 10UG)) and plated in 96 well Osteo Surface Assay plates (Corning) at 5000 cells per well. For wells receiving ZA treatment, the osteosurface was pre-coated for 30 minutes at 25°C with a 0, 2, 10, or 20 mM solution of ZA suspended in sterile water, followed by a gentle rinsing in PBS to remove free compound prior to plating of cells. Cells were treated with 10 pM KBU2046 or control for seven days with the media and treatment refreshed on day 4. On day 7, the wells were washed with PBS, and cellular material removed by a 5 min incubation in a 10% bleach solution followed by a through rinsing with Ultrapure water. To visualize the resultant osteoclast mediated pit formation, the intact mineralized matrix was stained following the manufacture's recommendations (Corning) utilizing a modified Von Kossa staining protocol. The resultant stained surfaces were imaged and subsequently evaluated using the "BoneJ" plugin of ImageJ. All treatments were performed in replicate of N=3, and were repeated. ApoTox-Glo assay
The ApoTox-Glo triplex assay (Promega) was performed to assess cell viability, cytotoxicity and caspase-3/7 activation, per manufacturer's instructions. In brief, 5000 Raw 264.7 cells were plated in 96- well assay plates and cultured in the osteoclasts differentiation media for four days at which point the media was replenished with or without KBU2046 and cell responses measured after 24, 48, and 72 hrs following the manufactures protocol.
Animal models of systemic effects and metastasis
All animal studies adhered to the NIH Guide for the Care and Use of Laboratory Animals, were treated under institutional lACUC-approved protocols by Oregon Health and Sciences University, complied with all federal, state, and local ethical regulations, and their design and implementation followed sanctioned guidelines (Hollingshead, Antitumor efficacy testing in rodents. J Natl Cancer Inst 100, 1500-1510 (2008)). Animals were housed in barrier (for immunocompromised mice) facilities, with a 12-h light/dark cycle and given soy-free food and water ad libitum. Animal study sample size determination: sample sizes were determined using the samples size estimation formula for differences in means with power set 80%, two-sided a = 0.05, and a pre-specified effect size of 30%.
PCa subcutaneous implantation: 2.5 x 105 PC3-M cells in sterile PBS were implanted into the right flank of 6-7 week old male athymic nude mice (Charles River) and tumor growth measurements were performed twice a week as previously described by us ( Gordon et al., Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One 9, el04271 (2014)). Treatment via oral gavage 5 days per week with 80mg/kg KBU2046 or vehicle control (sesame oil), as well as weekly intraperitoneal injections (IP) of docetaxel (0, 20mg/kg) began 18 days post implantation when tumors reached our enrollment criteria of "'200-300 mm3. Experimental groups were randomly assigned to cages prior to the initiation of the study. Tumor measurements were obtained in a blinded fashion, and tumor volumes were calculated with the following formula: length x (width)2 x 0.5.
PCa orthotopic implantation: Orthotopic implantation of 2.5 x 105 PC3M-luc into 7-8 week old male athymic mice was performed as previously described by us (5, 52 Xu et al., above; and Pavese et al., J Vis Exp, e50873 (2013)). Daily oral gavage treatment with 150mg/kg KBU2046 or was initiated 3 days prior to implantation and continued throughout the duration of the study. Weekly IP injections with 7.5 mg/kg docetaxel or control were administered beginning one week post implantation. Primary tumor out growth was monitored via weekly IVIS imaging. At the completion of the study the primary tumor was resected and weighed and lungs were resected and snap frozen. To determine the human PCa metastatic burden in each mouse lung, the snap frozen tissue was pulverized, DNA isolated and Alu- sequencing performed as previously described (19). The following custom TaqMan primer probe set was utilized: forward primer (101 F) GGTGAAACCCCGTCTCTACT, reverse primer (206 R) GGTTCAAGCGATTCT CCTGC, and hydrolysis probe (144RH) CGCCCGGCTAATTTTTGTAT. The 144RH probe was labeled with a 5' fluorescent reporter (6-FAM) and a 3' fluorescent quencher (Black Hole Quencher). The relative content of human DNA was calculated with using the comparative CT method, CT (sample) - CT (negative control). All samples were run in triplicate and were repeated.
Castration resistant PCa subcutaneous implantation: 6-7 week old male athymic mice received trans-scrotal bilateral orchiectomy with a single incision in the midline of scrotums under general anesthesia and then allowed to recover for 10 days. Following the recovery period mice received a subcutaneous implantation of 2.0 x 10s LNCaP/AR-luc into the right flank as previously described by us (Gordon et al., PLoS One 9, el04271 (2014)). Treatment with 80mg/kg KBU2046 or control was administered via oral gavage 5 times weekly starting 4 weeks post-implantation, prior to the emergence of the castration resistant phenotype, and continued for 12 weeks. Experimental groups were randomized prior to the initiation of treatment. Twice weekly tumor measurements were performed and androgen receptor activity monitored biweekly through IVIS imaging.
Castration resistant PCa orthotopic implantation: Castrations of athymic mice were performed as described above, and following a two-week recovery period orthotopic implantations of 5.0 x 105 LNCaP/AR-luc were performed as previously described by us (Xu et al., above; and, Pavese et al., above). Biweekly IVIS imaging was performed to assess androgen receptor activity and treatment with 80mg/kg KBU2046 or control via oral gavage 5 times weekly began 12 weeks post-implantation, as the castration resistant phenotype began to emerge, and continued for duration of 4 weeks. Experimental groups were randomly assigned to cages prior to the initiation of the study.
PCa intracardiac (1C) injection: 1C injection of 4.0 x 105 PC3-luc cells into the left ventricle of 7-8 week old athymic mice under ultrasound guidance was performed as previously described by us (Xu et al., above). Weekly IP injections of 100 pg/kg ZA or vehicle control (PBS) began 7 days prior to the 1C injection and continued throughout the duration of the study, whereas daily oral gavage treatment with 150mg/kg KBU2046 or control began 3 days prior to the 1C injection. All treatments were randomly assigned to cages prior to the initiation of the study. IVIS imaging was performed 30 min post 1C injection to confirm systemic distribution of cells and conducted weekly starting 7 days post injection, continuing for a period of 4 weeks. Animals were excluded from the analysis if 30-minute post-injection I VIS imaging revealed a focal signal only in the chest indicating a failed injection where cells were not distributed into circulation. Computed Tomograpgy (CT) radiographic imaging of the entire cohort was performed with an Inveon X-ray pCT scanner (Inveon, Siemens) at the completion of the study.
Resultant images were analyzed in a blinded fashion using Inveon Research Workplace 4.2
visualization/analysis software and ImageJ. Specifically, to assess metastasis-associated bone destruction, images were exported from the Inveon workplace in the Digital Imaging and
Communications in Medicine (DICOM) format for analysis in ImageJ. Each imported image was adjusted to a common brightness/contrast threshold and the "Stack -> Crop (3D)" and "volume viewer" plugins were utilized to perform multiplanar reconstruction (MPR) of regions of interest (mandible and femurs). Utilizing the MPR of the bilateral femurs, a blinded operator obtained step-section serial images of trabecular bone at both the proximal and distal ends of each femur. Subsequently, the "ROI manager" plugin was utilized to specify fixed regions of interest (ROIs) in each step-section images, and from which measurement bone density were obtained. Bone disruption of the mandible was assessed in a blinded fashion utilizing the MPR of the mandible. Flere, the loss of bone in the periodontal cavity was calculated by measuring the distance between the edge of molar root and the wall of periodontal cavity at both coronal and transverse planes.
Statistical analysis
For all experiments unless otherwise stated, comparisons between two groups were evaluated with the two-sided Student's t-test of fisher's exact test using a significance threshold of P < 0.05. Some experiments, as denoted, used Fisher exact test using a significance threshold of P < 0.05. In such instances, the mean value of the control group was used as the threshold to assign the categorical nature (i.e., >/ = versus < the mean value) of individual outcomes within different treatment groups.
Figures 6A through 6L: Experimental compounds inhibit osteoclast mediated bone degradation.
RAW 267.4 cells were plated onto Osteo Assay plates, in differentiation medium containing RANKL and the experimental compounds (or vehicle control) at the concentration indicated on day 0, medium was replenished with RANKL and treatments on day 3 day of the assay. To visualize the resultant osteoclast mediated pit formation, on day 6 wells were washed, cellular material removed, intact mineralized matrix was stained with a Von Kossa staining protocol, and images captured. Bone surface area was quantified, data are the mean ± SEM (N=2 replicates) of the remaining bone surface area, expressed as the percentage of control cells; *denotes P < 0.05 compared to control. Note: Black color denotes intact bone matrix.
Figure 7: Experimental compound inhibits PCa cell motility.
PC3M cells were plated with the indicated concentration of Compound E at day 0 and allowed to grow to confluency (48hrs), at which point a scratch wound was performed, wells were rinsed with PBS, media with treatment replenished, and images obtained at 0 hr and 20 post scratch. Data are N=24. * denotes P < 0.05, as measured by t-test.
Figures 8A and 8B: Experimental compounds inhibit movement of human prostate cancer cells.
PC3 cells were treated with 10 micromolar of compound E (n=l) for a total of 72 hrs, and placed into the upper well of uncoated (for migration) or collagen I coated (for invasion) Boyden chambers for the last 36 hours, and the number of cells in the lower chamber counted. Data are the mean +/- SEM, N = 4 replicates, expressed as % control cells.
Figure 9: Experimental compounds do not inhibit human prostate cancer cell viability.
Equal numbers of PC3 cells were plated under conditions permitting exponential cell growth, and one day later they were treated with 10 micromolar of compound E (n=l) for a total of 72 hrs, and cell viability measured using the ApoTox-Glo™ Triplex assay (Promega). Data are the mean +/- SEM, N = 4 replicates, expressed as relative fluorescent units.
Figure 10: Experimental compounds do not inhibit the viability of osteoclasts.
Equal numbers of RAW 267.4 cells were plated under conditions permitting exponential cell growth, and one day later they were treated with RANKL (to stimulate differentiation into mature osteoclasts) and treated with 10 micromolar of compound E (n=l) for a total of 72 hrs, and cell viability measured using the ApoTox-Glo™ Triplex assay (Promega). Data are the mean +/- SEM, N = 4 replicates, expressed as relative fluorescent units.
Figures 11A and 11B: Compound E (n=l) inhibits bone destruction.
Mice were treated with 0 (vehicle only), 10, 100 or 1000 ug/kg compound E (n=l) by weekly intraperitoneal injection, beginning 1 week before intracardiac (1C) injection of PC3-luc cells (PC3 cells that express luciferase). I VIS imaging was performed weekly, and at the end of the experiment, computed tomography (CT) scans performed and the degree of bone destruction in the jaw quantified. A total of N = 10 control mice (given vehicle only) were injected, and for each of the treatment cohorts, N = 10 mice were injected. * denotes P </= 0.05 by 2-sided Student's t test for comparisons between cohorts indicated by bars.
Figure 12: Compound E (n=l) prolongs survival.
Mice were are from Fig 5, and were treated with 0 (vehicle only), 10, 100 or 1000 ug/kg compound E (n=l) by weekly intraperitoneal injection, beginning 1 week before intracardiac (1C) injection of PC3-luc cells. Data depict survival of N = 10 mice per cohort, expressed as the percentage of mice at the beginning of the experiment (i.e., the day of 1C injection).
Figures 13-18: KBU2046 does not inhibit the efficacy of chemotherapy
For PC3-M PCa and MDA-MB-231 triple negative breast cancer cells, data are the mean ± SD (N = 2 replicates) number of colonies in 7 day colony formation assays. All data are expressed as the percentage of untreated control cells. Cells were treated with 10 mM KBU2046 or vehicle (CO), and the indicated concentration and type of chemotherapy.
Definitions
The compounds of the disclosure may possess an asymmetric center, and can be produced as a racemic mixture or as individual enantiomers. The individual enantiomers may be obtained by asymmetric synthesis or by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis. The individual enantiomers may also be obtained by resolution of the compound by conventional means, such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column. The individual enantiomers as well as racemic and non-racemic mixtures of enantiomers are within the scope of the present disclosure, all of which are intended to be included within the structures depicted in this specification unless otherwise specifically indicated.
As used in the specification and in the claims, the term "comprising" may include the embodiments "consisting of" and "consisting essentially of." The terms "comprise(s)," "include(s)," “having," "has,"“can," "contain(s)," and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence of the named ingredients/steps and permit the presence of other ingredients/steps. However, such description should be construed as also describing compositions or processes as "consisting of and "consisting essentially of the enumerated ingredients/steps, which allows the presence of only the named ingredients/steps, along with any impurities that might result therefrom, and excludes other ingredients/steps.
The terms "therapeutically effective amount" or "pharmaceutically effective amount" refer to an amount that is sufficient to effect treatment, as defined below, when administered to a subject (e.g., a mammal, such as a human) in need of such treatment. The therapeutically or pharmaceutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. For example, a "therapeutically effective amount" or a "pharmaceutically effective amount" of a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, is an amount sufficient to modulate a physiological expression or activity, and thereby treat a subject (e.g., a human) suffering an indication, or to ameliorate or alleviate the existing symptoms of the indication. For example, a therapeutically or pharmaceutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of activity. In some embodiments, the pharmaceutically effective dose per administration may be from about 1 mg to about 200 mg. In other embodiments, the pharmaceutically effective dose may be from about 5 mg to about 150 mg per dose. In other embodiments, the pharmaceutically effective dose may be from about 5 mg to about 100 mg per dose. In additional embodiments, the pharmaceutically effective dose may be from about 1 mg to about 50 mg.
For the treatment of osteoporosis, a medical professional may provide the dosage in a once- weekly regimen or divide the dosage into equal daily doses. For treatment of Paget's Disease of the bone, a single or divided dose may be administered every 1, 2, 3, 4, 5, or 6 months.
"Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: (i) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); (ii) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (e.g., metastasis) of the disease or condition);
and/or (iii) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival).
The terms "inhibiting" or "inhibition" indicates a decrease, such as a significant decrease, in the baseline activity of a biological activity or process. "Inhibition of a given activity" refers to a decrease in the activity as a direct or indirect response to the presence of a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, relative to the activity of the condition in the absence of such compound or a pharmaceutically acceptable salt or co-crystal thereof. The decrease in activity may be due to the direct interaction of the compound with a biological target, or due to the interaction of the compound(s) described herein with one or more other factors that in turn affect the specific activity. For example, the presence of the compound(s) may decrease an activity by directly binding to the target, by causing (directly or indirectly) another factor to decrease the activity, or by (directly or indirectly) decreasing the amount of a factor present in the cell or organism. In some embodiments, the inhibition of the specified activity may be compared in the same subject prior to treatment, or other subjects not receiving the treatment. The term "inhibitor" is understood to refer to a compound or agent that, upon administration to a human in need thereof at a pharmaceutically or therapeutically effective dose, provides the inhibition activity desired.
"Delaying" the development of a disease or condition means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease or condition, and/or subject being treated. A method that "delays" development of a disease or condition is a method that reduces probability of disease or condition development in a given time frame and/or reduces the extent of the disease or condition in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a statistically significant number of subjects. Disease or condition development can be detectable using standard methods, such as routine physical exams, mammography, imaging, or biopsy. Development may also refer to disease or condition progression that may be initially undetectable and includes occurrence, recurrence, and onset.
Numerical values in the specification and claims of this application should be understood to include numerical values which are the same when reduced to the same number of significant figures and numerical values which differ from the stated value by less than the experimental error of conventional measurement technique of the type described in the present application to determine the value.
All ranges disclosed herein, including the specification, abstract, and claims, are inclusive of the recited endpoint and independently combinable (for example, the range of "from 2 to 10" is inclusive of the endpoints, 2 and 10, and all the intermediate values).
By "significant" is meant any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p<0.05.
"Pharmaceutically acceptable salts" include, for example, salts with inorganic acids and salts with an organic acid. Examples of salts may include hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate (mesylate), benzenesuflonate (besylate), p-toluenesulfonate (tosylate), 2- hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate (such as acetate, HOOC-(CH2)n-- COOH where n is 0-4). In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts.
The term "crystal forms" and related terms herein refer to the various crystalline modifications of a given substance, including, but not limited to, polymorphs, solvates, hydrates, co-crystals, and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, other molecular complexes of salts, and polymorphs thereof. Crystal forms of a substance can be obtained by a number of methods, as known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces such as, e.g., in nanopores or capillaries, recrystallization on surfaces or templates, such as, e.g., on polymers, recrystallization in the presence of additives, such as, e.g., co-crystal counter-molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, grinding and solvent-drop grinding.
The term "co-crystal" or "co-crystal salt" as used herein means a crystalline material composed of two or more unique solids at room temperature, each of which has distinctive physical characteristics such as structure, melting point, and heats of fusion, hygroscopicity, solubility, and stability. A co-crystal or a co-crystal salt can be produced according to a per se known co-crystallization method. The terms co-crystal (or cocrystal) or co-crystal salt also refer to a multicomponent system in which there exists a host API (active pharmaceutical ingredient) molecule or molecules, such as a compound of Formula I, and a guest (or co-former) molecule or molecules. In particular embodiments the pharmaceutically acceptable co-crystal of the compound of Formula I or of the compound of Formula II with a co-former molecule is in a crystalline form selected from a malonic acid co-crystal, a succinic acid co-crystal, a decanoic acid co-crystal, a salicylic acid co-crystal, a vanillic acid co-crystal, a maltol co-crystal, or a glycolic acid co-crystal. Co-crystals may have improved properties as compared to the parent form (i.e., the free molecule, zwitter ion, etc.) or a salt of the parent compound. Improved properties can include increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, a crystalline form of a normally amorphous compound, a crystalline form of a difficult to salt or unsalable compound, decreased form diversity, more desired morphology, and the like.
The terms "subject" and/or "patient" refers to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful in both human therapy and veterinary applications. In some embodiments, the subject is a mammal; in some embodiments the subject is human; and in some embodiments the subject is chosen from cats and dogs. "Subject in need thereof" or "human in need thereof" refers to a subject, such as a human, who may have or is suspected to have diseases or conditions that would benefit from certain treatment; for example treatment with a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, as described herein. This includes a subject who may be determined to be at risk of or susceptible to such diseases or conditions, such that treatment would prevent the disease or condition from developing.
As used herein, "pharmaceutically acceptable excipient" is a pharmaceutically acceptable vehicle that includes, without limitation, any and all carriers, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
The term "carrier" refers to an excipient or vehicle that includes without limitation diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, and the like with which the compound is administered. Carriers are generally described herein and also in "Remington's Pharmaceutical Sciences" by E. W. Martin. Examples of carriers include, but are not limited to, aluminum monostearate, aluminum stearate, carboxymethylcellulose, carboxymethylcellulose sodium, crospovidone, glyceryl isostearate, glyceryl monostearate, hydroxyethyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxyoctacosanyl hydroxystearate, hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 188, poloxamer 237, poloxamer 407, povidone, silicon dioxide, colloidal silicon dioxide, silicone, silicone adhesive 4102, and silicone emulsion. It should be understood, however, that the carriers selected for the pharmaceutical compositions, and the amounts of such carriers in the composition, may vary depending on the method of formulation (e.g., dry granulation formulation, solid dispersion formulation).
The term "diluent" generally refers to a substance that is used to dilute the compound of interest prior to delivery. Diluents can also serve to stabilize compounds. Examples of diluents may include starch, saccharides, disaccharides, sucrose, lactose, polysaccharides, cellulose, cellulose ethers, hydroxypropyl cellulose, sugar alcohols, xylitol, sorbitol, maltitol, microcrystalline cellulose, calcium or sodium carbonate, lactose, lactose monohydrate, dicalcium phosphate, cellulose, compressible sugars, dibasic calcium phosphate dehydrate, mannitol, microcrystalline cellulose, and tribasic calcium phosphate.
The term "disintegrant" generally refers to a substance which, upon addition to a solid preparation, facilitates its break-up or disintegration after administration and permits the release of an active ingredient as efficiently as possible to allow for its rapid dissolution. Examples of disintegrants may include maize starch, sodium starch glycolate, croscarmellose sodium, crospovidone,
microcrystalline cellulose, modified corn starch, sodium carboxymethyl starch, povidone, pregelatinized starch, and alginic acid.
The term "precipitation inhibitors" generally refers to a substance that prevents or inhibits precipitation of the active agent from a supersaturated solution. One example of a precipitation inhibitor includes hydroxypropylmethylcellulose (HPMC). The term "surfactants" generally refers to a substance that lowers the surface tension between a liquid and a solid that could improve the wetting of the active agent or improve the solubility of the active agent. Examples of surfactants include poloxamer and sodium lauryl sulfate.
The term "glidant" generally refers to substances used in tablet and capsule formulations to improve flow-properties during tablet compression and to produce an anti-caking effect. Examples of glidants may include colloidal silicon dioxide, talc, fumed silica, starch, starch derivatives, and bentonite.
The term "binder" generally refers to any pharmaceutically acceptable film which can be used to bind together the active and inert components of the carrier together to maintain cohesive and discrete portions. Examples of binders may include hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone, copovidone, and ethyl cellulose.
The term "lubricant" generally refers to a substance that is added to a powder blend to prevent the compacted powder mass from sticking to the equipment during the tableting or encapsulation process. A lubricant can aid the ejection of the tablet form the dies, and can improve powder flow. Examples of lubricants may include magnesium stearate, stearic acid, silica, fats, calcium stearate, polyethylene glycol, sodium stearyl fumarate, or talc; and solubilizers such as fatty acids including lauric acid, oleic acid, and Cs/Cio fatty acid.
Pharmaceutical Compositions and Administration
Compounds of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, are usually administered in the form of pharmaceutical compositions. This disclosure therefore provides pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal or
pharmaceutically acceptable ester thereof, and one or more pharmaceutically acceptable vehicle, such as excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. The pharmaceutical compositions may be administered alone or in combination with other therapeutic agents. Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.). The pharmaceutical compositions may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
One mode for administration is parenteral, particularly by injection. The forms in which the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, may be
incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline may also conventionally be used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
Sterile injectable solutions are prepared by incorporating a compound according to the present disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. In some embodiments, for parenteral administration, sterile injectable solutions are prepared containing a therapeutically effective amount, e.g., 0.1 to 1000 mg, of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof. In some embodiments, the effective amount will be from about 0.1 mg to about 100 mg per dose. In other embodiments, the dosage will be from about 5 mg to about 75 mg per dose. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.
Oral administration is another route for administration of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof. Administration may be via capsule or enteric coated tablets, or the like. In making the pharmaceutical compositions that include the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
Some examples of suitable excipients in an oral formulation include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
The pharmaceutical compositions as described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770;
4,326,525; 4,902,514; and 5,616,345. Another formulation for use in the methods of the present disclosure employs transdermal delivery devices (patches). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present disclosure in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. In some embodiments, for parenteral administration, each dosage unit contains from 0.1 mg to 1 g, 0.1 mg to 700 mg, or 0.1 mg to 100 mg of a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof.
For any of the dosage units as described herein, it will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
The tablets or pills as described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
Compositions for inhalation or insufflation may include solutions and suspensions in
pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions comprising the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, may contain suitable pharmaceutically acceptable excipients as described supra. Preferably, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
The compounds, pharmaceutical compositions, and methods of treatment herein may be used in combination with other forms of cancer treatment, including chemotherapy, other bone directed therapy, inclusive of bisphosphonates or denosumab, hormone therapy, radiation therapy, surgery, small molecule therapeutics (imatinib, cisplatin, doxorubicin, Ifosfamide, methotrexate, vincristine, cyclophosphamide, etoposide, dactinomycin, eribulin mesylate, larotrectinib, pazopanib, trabectedin), including inhibitors of protein kinases, interferon, mTOR inhibitors (rapamycin, temsirolimus, everolimus, ridaforolimus), PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, AZD2281), biologies, including antibodies (trastuzumab, denosumab, glembatumumab, lexatumumab, cixutumumab, ipilimumab, bevacizumab, olaratumab) , directed towards protein kinases or immune checkpoint regulators (PD-1 inhibitors, such as pembrolizumab, nivolumab, and cemiplimab; PD-L1 inhibitors atezolizumab, avelumab, and durvalumab), and regulators of angiogenesis (PF-4, TSP-1, angiostatin, endostatin).
For the treatment of bone cancers, including metastatic bone cancers, the compounds herein may be administered in combination treatments utilizing chemotherapeutic agents such as taxol, vinblastine, vincristine, Ifosfamide (IFEX®), doxorubicin (ADRIAMYCIN®), etoposide, methotrexate, cisplatin, dactinomycin, denosumab, and cyclophosphamide (CYTOXAN®), or combinations thereof.
For the treatment of osteoporosis and bone loss, the compounds herein may be utilized in combination therapies with additional agents, such as alendronate (FOSOMAX®), risedronate
(ACTONEL®), ibandronate (BONIVA®), etidronate (DIDRONEL®), zolendronic acid (RECLAST®, ZOMETA®), denosumab (PROLIA®, XGEVA®), teriparatide (FORTEO®), abaloparatide (TYMLOS®), raloxifine (EVISTA®), teriparatide (FORTEO®), denosumab (PROLIA®), and calcitonin (MIACALCIN®, FORTICAL®),
romosozumab, estrogen, conjugated estrogens (PREMARIN®), conjugated estrogens with
medroxyprogesterone (PREMPRO®, PREMPHASE®), esterified estrogens (M ENEST®), estradiol, estropipate, as well as calcium and calcium salt supplements.
Articles of Manufacture and Kits
Compositions (including, for example, formulations and unit dosages) comprising the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, can be prepared and placed in an appropriate container, and labeled for treatment of an indicated condition. Accordingly, provided is also an article of manufacture, such as a container comprising a unit dosage form of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, and a label containing instructions for use of the compounds. In some embodiments, the article of manufacture is a container comprising a unit dosage form of the compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof, and at least one pharmaceutically acceptable vehicle. The article of manufacture may be a bottle, vial, ampoule, single-use disposable applicator, or the like, containing the pharmaceutical composition provided in the present disclosure. The container may be formed from a variety of materials, such as glass or plastic and in one aspect also contains a label on, or associated with, the container which indicates directions for use in the treatment of cancer of the bone. It should be understood that the active ingredient may be packaged in any material capable of improving chemical and physical stability, such as an aluminum foil bag. In some embodiments, diseases or conditions indicated on the label can include, for example, treatment of cancer of the bone which is original in origin to bone. In other embodiments, the label may be directed to treatment of a cancer that has metastasized to the bone.
Any pharmaceutical composition provided in the present disclosure may be used in the articles of manufacture, the same as if each and every composition were specifically and individually listed for use in an article of manufacture.
Also provided is a kit that includes a compound of Formula I, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof. Also provided is a kit that includes a compound of Formula II, or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof. In one aspect, the kit comprises a compound of Formula I, or a pharmaceutically acceptable salt or co-crystal thereof. In a further aspect, the kit comprises a compound of Formula II, or a pharmaceutically acceptable salt or co-crystal thereof. The kit may comprise a label and/or instructions for use of the compound in the treatment of a disease or condition in a subject (e.g., human) in need thereof. In some embodiments, the disease or condition may be associated with or mediated by the intended activity.

Claims

What is claimed:
1. A compound of the formula:
Figure imgf000063_0001
wherein:
Z is selected from the group of:
Figure imgf000063_0002
ni in each instance is an integer selected from the group of 1, 2, 3, 4, 5, and 6;
X is (-CH2-)n2;
Ri is selected from the group of H and Ci-C3 alkyl;
R2 is selected from the group of H and OH;
n2 is an integer selected from the group of 0, 1, 2, and 3;
n3 is an integer selected from the group of 0 and 1;
and
Y is a bisphosphonate compound;
or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
2. The compound of Claim 1, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, wherein the bisphosphonate compound designated by Y is selected from the group of:
Figure imgf000064_0001
3. The compound of Claims 1, wherein the compound of Formula (I) is of Formula (II), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof:
Figure imgf000065_0001
wherein: ni is an integer selected from the group of 1, 2, 3, and 4; and n3 is an integer selected from the group of 0 and 1.
4. The compound of Claims 3, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, having the formula:
Figure imgf000065_0002
5. The compound of Claim 3, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, having the formula:
Figure imgf000066_0001
6. The compound of Claim 3, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, having the formula:
Figure imgf000066_0002
7. The compound of Claim 3, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, having the formula:
Figure imgf000066_0003
8. The compound of Claim 1, wherein the compound of Formula (I) is of Formula (lb), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof:
Figure imgf000067_0002
Z is selected from the group of:
Figure imgf000067_0001
ni is an integer selected from 1, 2, 3, and 4;
X is (-CH2-)n2;
Ri is selected from the group of H and C1-C3 alkyl;
R2 is selected from the group of H and OH; n2 is an integer selected from 0, 1, 2, and 3; n3 is an integer selected from the group of 0 and 1; and Y is a bisphosphonate compound; or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
9. The compound of Claim 8, wherein the compound of Formula (lb) is of Formula (lc), or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof:
Figure imgf000068_0001
wherein:
Ri is selected from H and methyl;
ni is an integer selected from the group of 1, 2, and 3;
n3 is an integer selected from the group of 0 and 1; and
Z is selected from the group of:
Figure imgf000068_0002
or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
10. The compound of Claim 9, wherein the compound has the formula:
Figure imgf000068_0003
or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
11. The compound of Claim 9, wherein the compound has the formula:
Figure imgf000069_0001
or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
12. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Claim 1, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof, and a pharmaceutically acceptable carrier or excipient.
13. A method of treatment of osteoclast mediated bone degradation in a subject, the method comprising administering to a subject in need thereof a pharmaceutically effective amount of the compound of Claim 1, or a pharmaceutically acceptable salt, co-crystal, polymorph, solvate, hydrate, or enantiomer thereof.
PCT/US2020/017071 2019-02-06 2020-02-06 Bisphosphonate-linked compounds WO2020163637A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021545859A JP2022523146A (en) 2019-02-06 2020-02-06 Bisphosphonate linking compound
EP20752874.6A EP3920906A4 (en) 2019-02-06 2020-02-06 Bisphosphonate-linked compounds
US17/428,951 US20220133894A1 (en) 2019-02-06 2020-02-06 Bisphosphonate-linked compounds
CA3128239A CA3128239A1 (en) 2019-02-06 2020-02-06 Bisphosphonate-linked compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962801858P 2019-02-06 2019-02-06
US62/801,858 2019-02-06

Publications (1)

Publication Number Publication Date
WO2020163637A1 true WO2020163637A1 (en) 2020-08-13

Family

ID=71947917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/017071 WO2020163637A1 (en) 2019-02-06 2020-02-06 Bisphosphonate-linked compounds

Country Status (5)

Country Link
US (1) US20220133894A1 (en)
EP (1) EP3920906A4 (en)
JP (1) JP2022523146A (en)
CA (1) CA3128239A1 (en)
WO (1) WO2020163637A1 (en)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5616345A (en) 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
US20100137425A1 (en) * 2008-10-10 2010-06-03 Northwestern University Inhibition and treatment of prostate cancer metastasis
US20110065672A1 (en) 2009-09-16 2011-03-17 Mount Sinai School Of Medicine Of New York University Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis
WO2012098222A1 (en) * 2011-01-21 2012-07-26 Universita' Degli Studi Magna Graecia Di Catanzaro Bisphosphonate-polyaspartamide conjugates as polymeric carriers for drug targeting to bones
US20140051623A1 (en) 2011-02-24 2014-02-20 Ktb Tumorforschungsgesellschaft Mbh Bisphosphonate-Prodrugs
US20160128973A1 (en) 2014-11-06 2016-05-12 Northwestern University Inhibition of cancer cell motility
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
US20160311805A1 (en) * 2015-04-27 2016-10-27 Pfizer Inc. Anti-estrogenic compounds
WO2019007447A1 (en) 2017-07-05 2019-01-10 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5616345A (en) 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US20100137425A1 (en) * 2008-10-10 2010-06-03 Northwestern University Inhibition and treatment of prostate cancer metastasis
US20110065672A1 (en) 2009-09-16 2011-03-17 Mount Sinai School Of Medicine Of New York University Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis
WO2012098222A1 (en) * 2011-01-21 2012-07-26 Universita' Degli Studi Magna Graecia Di Catanzaro Bisphosphonate-polyaspartamide conjugates as polymeric carriers for drug targeting to bones
US20140051623A1 (en) 2011-02-24 2014-02-20 Ktb Tumorforschungsgesellschaft Mbh Bisphosphonate-Prodrugs
US20160128973A1 (en) 2014-11-06 2016-05-12 Northwestern University Inhibition of cancer cell motility
US20180153853A1 (en) * 2014-11-06 2018-06-07 Northwestern University Inhibition of cancer cell motility
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
US20160311805A1 (en) * 2015-04-27 2016-10-27 Pfizer Inc. Anti-estrogenic compounds
WO2019007447A1 (en) 2017-07-05 2019-01-10 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"Modern Pharmaceutics", MARCEL DEKKER, INC.
"Remington's Pharmaceutical Sciences", 1985, MACE PUBLISHING CO.
ALEJANDRO, J. D. JOHNSON: "Inhibition of Raf-1 alters multiple downstream pathways to induce pancreatic beta-cell apoptosis", J BIOL CHEM, vol. 283, 2008, pages 2407 - 2417
BEER ET AL., N ENGL J MED, vol. 371, 2014, pages 424 - 433
BONO ET AL., LANCET, vol. 376, 2010, pages 1147 - 1154
BRADLEY ET AL., J CELL BIOCHEM, vol. 104, 2008, pages 1439 - 1451
C. LOGOTHETIS ET AL., CANCER METASTASIS REV, vol. 37, 2018, pages 189 - 196
CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 39, no. 10, 1991, pages 2681 - 90
CHU ET AL., MOL CANCER RES, vol. 6, 2008, pages 1259 - 1267
DING ET AL., J BIOMOL TECH, vol. 18, 2007, pages 321 - 330
FANG ET AL., J BIOL CHEM, vol. 271, 1996, pages 28697 - 28702
FARRELL ET AL., BONE REP, vol. 9, 2018, pages 47 - 60
FLORENCIO-SILVA ET AL., BIOMED RES INT, vol. 2015, 2015, pages 421746
FUNAKOSHI ET AL., SCI REP, vol. 7, 2017, pages 13202
FURR ET AL., EUR UROL, vol. 29, 1996, pages 83 - 95
GORDON ET AL., PLOS ONE, vol. 9, 2014, pages e104271
GORDON ET AL.: "Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes", PLOS ONE, vol. 9, 2014, pages e104271, XP055942107, DOI: 10.1371/journal.pone.0104271
GUISE ET AL., ENDOCR REV, vol. 19, 1998, pages 18 - 54
GUISE, J MUSCULOSKELET NEURONAL INTERACT, vol. 2, 2002, pages 570 - 572
HE ET AL., PLOS ONE, vol. 6, 2011, pages e24780
HUSSAIN ET AL., Λ/ ENGL J MED, vol. 378, 2018, pages 2465 - 2474
J NATL CANCER INST, vol. 100, 2008, pages 1500 - 1510
JAMES ET AL., JAMA ONCOL, vol. 2, 2016, pages 493 - 499
KORENCHUK ET AL., IN VIVO, vol. 15, 2001, pages 163 - 168
LAKSHMAN ET AL., CLIN EXP METASTASIS, vol. 28, 2011, pages 39 - 53
LI XU ET AL., NAT. COMM., vol. 9, no. 1, 2018
LIU ET AL., PROSTATE CANCER AND PROSTATIC DISEASES, vol. 4, 2001, pages 81 - 91
LIVAK ET AL., METHODS, vol. 25, 2001, pages 402 - 408
LYSENG-WILLIAMSON ET AL., DRUGS, vol. 65, 2005, pages 2513 - 2531
NAKAMURA ET AL., J BONE MINER RES, vol. 18, 2003, pages 1198 - 1205
NI ET AL., MOL CELL BIOL, vol. 30, 2010, pages 1243 - 1253
NORGAARD ET AL., J UROL, vol. 184, 2010, pages 162 - 167
PAVESE ET AL., CANCER LETT, vol. 352, 2014, pages 179 - 186
PAVESE ET AL., J VIS EXP, 2013, pages e50873
POLASCIK ET AL., THER CLIN RISK MANAG, vol. 4, 2008, pages 261 - 268
POUND ET AL., JAMA, vol. 281, 1999, pages 1591 - 1597
SAAD ET AL., J NATL CANCER INST, vol. 94, 2002, pages 1458 - 1468
SAAD ET AL., J NATL CANCER INST, vol. 96, 2004, pages 879 - 882
SAPORITA ET AL., PROSTATE, vol. 67, 2007, pages 509 - 520
SEYFRIED ET AL., CRIT REV ONCOG, vol. 18, 2013, pages 43 - 73
SWEENEY ET AL., N ENGL J MED, vol. 373, 2015, pages 737 - 746
TANNOCK ET AL., N ENGL J MED, vol. 351, 2004, pages 1502 - 1512
TRAN ET AL., SCIENCE, vol. 324, 2009, pages 787 - 790
TSAUR ET AL., UROLOGIC ONCOLOGY, vol. 36, 2018, pages 488 - 497
XU ET AL., NATURE COMMUNICATIONS, vol. 9, 2018, pages 2454
YOTOVA ET AL., J CELL MOL MED, vol. 16, 2012, pages 2127 - 2139
ZHANG ET AL.: "A Multifunctional Therapy Approach for Cancer: Targeting Rafi-Mediated Inhibition of Cell Motility, Growth, and Interaction with Microenvironment", MOLECULAR CANCER THERAPEUTICS, vol. 19, no. 1286281-32-0, January 2020 (2020-01-01), pages 39 - 51

Also Published As

Publication number Publication date
US20220133894A1 (en) 2022-05-05
EP3920906A1 (en) 2021-12-15
CA3128239A1 (en) 2020-08-13
JP2022523146A (en) 2022-04-21
EP3920906A4 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
RU2767664C2 (en) Combination therapy with anticancer alkaloid
DK2694072T3 (en) COMBINATION OF ACT-INHIBITOR RELATIONSHIP AND ABIRATERON FOR USE IN THERAPEUTIC TREATMENTS
JP6754071B2 (en) Combination medications containing metformin and dihydroquercetin, and use for the treatment of cancer
US20040152759A1 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
EA028452B1 (en) Treatment of breast cancer
KR20130045341A (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
AU2015314753A1 (en) Human dosing of phosphatase inhibitor
JP2012520299A (en) Kinase protein binding inhibitor
TW201831191A (en) Novel boric acid derivative and pharmaceutical composition using same
TW201039817A (en) Pyrrolidine substituted flavones as radio sensitizers
US9539237B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
TWI557128B (en) Use of a composition for the manufacture of a medicament for preventing or treating nsclc
WO2020163637A1 (en) Bisphosphonate-linked compounds
WO2012082992A1 (en) Compositions and methods for cancer treatment
TW201242597A (en) A synergistic pharmaceutical combination for the treatment of pancreatic cancer
WO2016135138A1 (en) Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2018158175A1 (en) Combination of bub1 inhibitors
US10857113B2 (en) Bezafibrate for the treatment of cancer
EP3878444B1 (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
CN111432815A (en) Enhancing cancer treatment efficacy via sphingosine-1-phosphate pathway
KR20130140052A (en) Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl)-n&#39;-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferative disorders
WO2016135140A1 (en) 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
Sighel Inhibition of mitochondrial translation as a novel strategy to eradicate glioblastoma stem cells
JP2019532937A (en) Combination therapy strategy for cancer based on RNA polymerase I inhibition
TW200307533A (en) Use of EDG receptor binding agents in cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20752874

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3128239

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021545859

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020752874

Country of ref document: EP

Effective date: 20210906